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ABSTRACT
THE ROLE OF SKIN RESIDENT CD4 T CELLS IN CUTANEOUS LEISHMANIASIS
Nelson D. Glennie
Phillip Scott, Ph.D.

Cutaneous leishmaniasis is a disease characterized by highly inflammatory, sometimes
disfiguring lesions that nonetheless spontaneously resolve, resulting in robust protection
against reinfection. It has been known for decades that a type 1 CD4+ T cell response is
critical for both primary parasite control and subsequent protection against reinfection.
However, all attempts to artificially reproduce this response have failed, suggesting there
may be a gap in our understanding of the memory CD4+ T cells generated by natural
infection. In this work, we use a healing mouse model of cutaneous leishmaniasis to
explore the role of skin-associated CD4+ T cells in this disease. We demonstrate for the
first time that tissue-resident memory (TRM) CD4+ T cells are generated by leishmania
infection, are long-lived, and are distributed throughout the skin. We next investigate
whether or not these cells contribute to immune protection, and find that leishmaniaspecific TRM cells can guide the rapid recruitment of circulating T effector cells to the site
of challenge, enhancing control of infection. We go on to identify another, novel
mechanism of TRM cell-driven protection, in which leishmania-specific TRM cells
orchestrate the rapid infiltration and activation of inflammatory monocytes, leading to
robust early control of disease even in the absence of circulating T cells. Finally, we
explore the requirements for the establishment of TRM cell populations in cutaneous
leishmaniasis, with the ultimate goal of understanding how to harness these cells in a
potential vaccine.
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CHAPTER 1: Introduction
1.1 Leishmaniasis
Leishmaniasis, a disease caused by many different species of the intracellular protozoan
parasite leishmania, remains a serious global public health problem. According to
estimates, roughly 1 million new infections occur each year, and hundreds of millions
more are at risk of infection (World Health Organization, 2017). The disease is
transmitted by the sand fly, with endemic areas of disease falling predominantly in
equatorial regions that support the arthropod vector. As the global climate continues to
change, it is predicted that the range of the sand fly will expand further, putting even
more people at risk for infection (Iba et al., 2013).

The life cycle of leishmania is relatively simple (Kaye and Scott, 2011). The parasites
are transmitted by sand flies that harbor the flagellated promastigote form of the
parasite. When feeding, sand flies deposit promastigotes in the skin, and phagocytic
cells rapidly take up the parasites. While the initial cells that become infected include
neutrophils, macrophages, and monocytes, it is primarily within macrophages that the
parasites survive and replicate as non-flagellated amastigotes. Surprisingly, unlike other
intracellular parasites, such as toxoplasma or Trypanosoma cruzi, leishmania survives
and replicates within the phagolysome, having evolved the ability to persist in an
environment meant to destroy most microbes. After several rounds of replication, the
amastigotes rupture the infected cell and invade other neighboring macrophages. The
parasites differentiate back into promastigotes when taken up by sand flies, continuing
the infectious cycle.
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Leishmaniasis is characterized by diverse clinical entities ranging from self-healing
cutaneous lesions, to severe, disfiguring chronic lesions, and even causes fatal disease
in its visceral form. Drug treatment for leishmaniasis is notoriously poor and, despite
decades of research, there is no vaccine for this disease, creating a continuing need for
the development of new therapies. Antibodies play no protective role, and indeed may
exacerbate disease (Miles et al., 2005). CD8+ T cells may play a protective role in
certain contexts (Uzonna et al., 2004; Müller et al., 1994), but have also been implicated
in the exacerbation of the disease (Crosby et al., 2014; Novais et al., 2013). In contrast,
CD4+ T cells are the cells required for control, specifically IFNγ produced by these cells,
which activates infected macrophages to kill the parasites. Thus, the inability to develop
a successful vaccine is largely due to a lack of knowledge on how to generate long-lived
memory CD4+ T cells (Kaye and Scott, 2011). Studying the CD4+ T cell subsets
involved in protective immunity against leishmaniasis is an opportunity with the potential
to improve prophylactic treatments for this disease.

1.2 Protective mechanisms in cutaneous leishmaniasis
The production of reactive oxygen species (ROS) during phagocytosis, called the
respiratory burst, is an innate response that allows macrophages and neutrophils to kill
microbes before the development of an adaptive response. Those microbes that survive
innate killing become pathogens that require a greater response for elimination, which
can be induced by the action of IFNγ. This IFNγ response leads to increased production
of ROS, as well as activation of inducible nitric oxide synthase, leading to the release of
nitric oxide (NO). Leishmania parasites are killed by both ROS and NO, but different
myeloid cells may be better able to kill by one mechanism than the other. For example,
2

inflammatory monocytes exhibit a high level of ROS and can kill leishmania without
being activated, while macrophages require IFNγ activation for killing (Novais et al.,
2014; Goncalves et al., 2011). Under some circumstances neutrophils cooperate with
macrophages to kill the parasites (Novais et al., 2009), although in other situations
neutrophils appear to inhibit parasite control (Afonso et al., 2008). Further complicating
the matter, although it is clear that NO is required for the ability of mouse macrophages
to kill leishmania, the role of NO in human cells remains controversial (Novais et al.,
2014; Carneiro et al., 2016; Vouldoukis et al., 1995). Nonetheless, in both mice and
humans IFNγ is absolutely required to activate infected phagocytes to eliminate
parasites, leading to control of the disease.

Many cell types can produce IFNγ, including NK cells, ILCs, γδ T cells, CD4+ T cells and
CD8+ T cells. However, while all IFNγ producing cells may contribute to an effective
response, only CD4+ T cells can transfer resistance against leishmania infection to
reconstituted RAG-/- mice (Belkaid et al., 2002a; b; Novais et al., 2013). The critical
attribute of these cells appears to be their MHC restriction, since it was recently found
that adoptive transfer of class II restricted, but double negative (CD4-, CD8-) T cells,
also provides resistance to leishmania (Mou et al., 2014). Nevertheless, while not
protective by themselves, other IFNγ producing cells can play important roles in
augmenting protection. NK cells (and possibly other innate lymphoid cells) accelerate
the development of a Th1 response when CD4+ T cells are being primed in the draining
lymph nodes (Laouar et al., 2005; Prajeeth et al., 2011; Scharton and Scott, 1993).
Similarly, following a low dose challenge, IFNγ from CD8+ T cells promotes the CD4+
Th1 response (Uzonna et al., 2004). Nonetheless, CD4+ T cells remain the predominant
source of protective IFNγ, and will be the focus of this work.
3

1.3 Complexities of the immune response to leishmaniasis
There are some unusual aspects of the immune response to leishmania that are worth
noting. First, it is important to consider that control of the parasites and the development
of disease are often dissociated. This is most evident in L. braziliensis patients with
mucosal disease, where the severe lesions are chronic and debilitating, but contain few
parasites. Conversely, while RAG-/- mice are unable to control parasite replication, they
develop only minor swelling at the site of infection. Adoptive transfer of CD4+ T cells to
these immunocompromised mice is sufficient to allow for parasite control, but may lead
to the development of larger lesions, although these lesions generally resolve,
depending on the leishmania species (Belkaid et al., 2002b; Novais et al., 2013; Soong
et al., 1997). On the other hand, when RAG-/- mice are reconstituted with CD8+ T cells
they not only fail to control the parasites, but also develop a severe inflammatory
response, as well as the development of metastatic lesions (Belkaid et al., 2002b;
Novais et al., 2013). This is a surprising result, since under certain circumstances CD8+
T cells can promote protection (Uzonna et al., 2004; Muller et al., 1993; Müller et al.,
1994). It turns out that whether CD8+ T cells promote resistance or increased disease
relates directly to whether they primarily produce IFNγ or are cytolytic, as increased
cytolytic activity promotes a pathologic inflammatory response (Novais et al., 2013;
Santos et al., 2013). Since we will focus on IFNγ-producing CD4+ T cells that are rarely
associated with immunopathology, this work will emphasize mechanisms required for
parasite control.

Although there is a shared pathway for resistance to leishmania that requires IFNγ, there
are many different strains and species of the parasites, adding additional complexity to
the disease. These different species can induce distinct immune responses, and have
4

differential sensitivities to macrophage killing. This is particularly true of species in
South America, which can produce chronic infections in mice normally resistant to L.
major (McMahon-Pratt and Alexander, 2004). One example is L. amazonensis, which
induces a chronic disease in C57BL/6 mice (Khouri et al., 2009). L. amazonensis
parasites induce a weaker CD4+ Th1 response than L. major infection, and are also able
to resist killing by activated macrophages that can kill L. major (Scott et al., 1983). Even
within the same leishmania species, different strains can lead to diverse outcomes
following infection (Anderson et al., 2005). From this, one might conclude that vaccines
and the memory T cells they generate might be effective against one species or strain of
leishmania, but less effective against another. On the other hand, several studies have
shown cross-protection between species, providing some evidence that a single vaccine
may work for different leishmania parasites, and even protect against the visceral form of
the disease (Romano et al., 2015; Mou et al., 2015). In all our studies we will use the
Friedlin strain of Leishmania major as a representative cutaneous leishmania infection,
but anticipate that our findings may have broader relevance despite inevitable speciesspecific differences.

1.4 Protective CD4+ T cells in cutaneous leishmaniasis
Following resolution of a primary infection, mice and humans are highly resistant to
reinfection with leishmania. As aforementioned, this resistance is primarily dependent
upon CD4+ T cells, although other IFNγ-producing cells can contribute to immunity in
some situations (Muller et al., 1993; Müller et al., 1994; Okwor et al., 2014). For the
interest of this work, we will focus on what is known about the CD4+ T cell subsets
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involved in providing protection, specifically effector T cells (TEff), effector memory T cells
(TEM), and central memory T cells (TCM).

The strong resistance observed in healed mice is dependent in part on the persistence
of a low number of parasites (Uzonna et al., 2001; Belkaid et al., 2002a). Thus, the few
parasites that are left after the resolution of a primary infection maintain a pool of true
CD4+ TEff cells that can rapidly respond to a challenge. TEff cells from immune mice, as
defined by low expression of CD62L, have been shown to transfer protection against
disease due to their ability to home to the site of infection and rapidly produce cytokine
(Zaph et al., 2004). Recently, this population of short-lived TEff cells has been even more
thoroughly characterized (Peters et al., 2014). These cells phenotypically resemble the
CD4+ TEff cells generated after viral infection (Marshall et al., 2011) in that they express
high levels of Ly6C and T-bet, produce IFNγ at a high frequency upon activation, and, as
previously demonstrated, can transfer rapid protection (Peters et al., 2014).
Unfortunately, these cells fail to persist in the absence of antigen (Zaph et al., 2004;
Peters et al., 2014), and are thus difficult to target for vaccine-induced protection despite
being highly protective in natural infection.

In contrast to TEff cells, memory T cells are defined by their ability to be maintained in the
absence of antigen once an infection is cleared. Memory CD4+ T cells have classically
been divided into two subsets, central memory (TCM) and effector memory (TEM) cells,
based on surface marker expression, tissue tropism, proliferative capacity, and effector
function (Sallusto et al., 1999). Central memory T cells express CD62L and CCR7,
which allow them to efficiently traffic through the blood and lymph nodes. Upon
restimulation, TCM cells rapidly proliferate and thus provide a pool of differentiated,
6

antigen-specific cells to combat a secondary infection. In contrast, TEM cells lack CD62L
and CCR7, circulate through blood and non-lymphoid tissues, and exhibit effector
functions, such as cytokine production and cytotoxicity, upon restimulation. T EM cells are
often distinguished from closely related T effector cells by their ability to persist after
antigen is cleared, but can also be identified by IL-7R expression on CD8+ T cells
(Kaech et al., 2003), and additionally by the absence of Ly6C expression on CD4+ T
cells (Marshall et al., 2011).

In the context of leishmania infection, since the parasites persist chronically, we must
rely exclusively on phenotypic and functional markers to distinguish memory cell
subsets. To this end, it was once a question of whether or not memory CD4+ T cells
would exist in leishmaniasis at all. However, there is indeed a population of CD62L high
CD4+ T cells that demonstrate TCM cell activity by rapidly proliferating to generate TEff
cells upon restimulation with leishmania antigen (Zaph et al., 2004). Further, when
transferred to naïve recipients these CD62L high cells can provide protection, albeit
delayed in comparison to CD62 low TEff cells (Zaph et al., 2004). Importantly, these
CD62L high cells can persist and transfer protection in the absence of antigen, as
demonstrated using a replication-deficient parasite (Zaph et al., 2004). Intriguingly,
antigen-specific CD62L+CCR7+ cells can be identified within the first couple weeks of
infection, indicating that TCM and TEff cells are generated concurrently. This cell fate
decision appears to be affected by the timing of antigen experience and the number of
proliferative cycles a cell has gone through (Colpitts and Scott, 2010). TCM cells are not
only a critical component of secondary protection, but also an appealing target for
vaccination since they have the ability to proliferate to provide a robust pool of TEff cells,
and because they are maintained in the absence of persistent antigen.
7

Not surprisingly, the role for TEM cells in leishmania infection is less defined, as it
becomes difficult to distinguish these cells from TEff cells maintained by the chronic
infection. Nonetheless, there is evidence that leishmania infection generates a
population of antigen experienced CD62L-IL-7R+Ly6C- cells (Colpitts et al., 2009), that fit
the TEM cell phenotype. However, the role for these cells in protection remains unclear
as they may not be able to migrate to the infection site or proliferate effectively following
challenge (Peters et al., 2014). For simplicity, we will group circulating T cell responses
into TEff or TCM cells in leishmaniasis, as they are the most easily distinguishable and
most relevant cell types.

1.5 Resident Memory T cells
In addition to circulating TCM and TEff cells, a new subset of non-migratory memory T
cells that resides in non-lymphoid tissue has been classified as resident memory T cells
(TRM). These cells were first discovered in the gut (Kim et al., 1999; Masopust et al.,
2001) and lung (Hogan et al., 2001a; b) around the same time TCM and TEM cells were
first being defined (Sallusto et al., 1999), but were initially thought by many to be TEM
cells in transit through the tissue because of their phenotypic similarity to TEM cells
(Masopust et al., 2001). Although some distinctions from TEM cells suggested that these
tissue cells might be a unique cell subset (Kim et al., 1999; Hogan et al., 2001a;
Masopust et al., 2006), it was not until more recently that transplantation (Gebhardt et
al., 2009) and parabiotic surgery (Jiang et al., 2012) confirmed that TRM cells in tissue
could persist in the tissue at disequilibrium from cells in circulation, and in the absence of
any antigen exposure (Casey et al., 2012).
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TRM cells have now been identified, characterized, and demonstrated to promote
protection in such diverse tissues as the gut (Kim et al., 1999; Masopust et al., 2001,
2006; Bergsbaken and Bevan, 2015; Bergsbaken et al., 2017), lung (Hogan et al.,
2001a; b; Cauley et al., 2002; Ely et al., 2003; Teijaro et al., 2011; Laidlaw et al., 2014;
Wu et al., 2013; Purwar et al., 2011), skin (Clark et al., 2006; Gebhardt et al., 2009;
Jiang et al., 2012; Gaide et al., 2015; Watanabe et al., 2015; Collins et al., 2016), brain
(Wakim et al., 2010, 2012; Steinbach et al., 2016), female reproductive tract (Schenkel
et al., 2013; Schenkel, 2014; Shin and Iwasaki, 2012; Iijima and Iwasaki, 2014), liver
(Tse et al., 2013), salivary glands (Hofmann and Pircher, 2011; Thom et al., 2015), and
even secondary lymphoid organs (Schenkel et al., 2014b). While initial studies
described TRM cells that provided protection against acute viral infections, (Gebhardt et
al., 2009; Teijaro et al., 2011; Jiang et al., 2012; Schenkel et al., 2013), these findings
have now been extended to a number of bacterial (Sakai et al., 2014; Bergsbaken and
Bevan, 2015; Bergsbaken et al., 2017), and even parasitic (Tse et al., 2013) infections.

Many of the initial TRM studies were performed on CD8+ T cells (Kim et al., 1999; Hogan
et al., 2001a; Masopust et al., 2001, 2006; Gebhardt et al., 2009; Jiang et al., 2012), but
it is now clear that CD4+ cells also form TRM cell populations (Teijaro et al., 2011; Iijima
and Iwasaki, 2014; Laidlaw et al., 2014; Collins et al., 2016). While these CD4+ and
CD8+ TRM cells share some important characteristics in that they reside in tissue and
enhance early protection, distinctions have been identified regarding their location,
migratory properties, and function. In skin, it has been found that HSV-specific CD8+
TRM cells are associated with the epidermis, while CD4+ cells are more likely to be found
in the dermis (Gebhardt et al., 2011). Moreover, while both CD4+ and CD8+ T cells are
seen to associate with hair follicles, CD8+ T cells show an increased dependence on IL9

15 signaling (Adachi et al., 2015), while CD4+ cells have been showed to demonstrate
clustering behavior both in the skin (Collins et al., 2016) and the female reproductive
tract (Iijima and Iwasaki, 2014) where they rely on myeloid cell networks for
maintenance. CD4+ cells are also much more likely to be migratory within tissue (Debes
et al., 2005; Gebhardt et al., 2011; Bromley et al., 2012; Collins et al., 2016), while a
majority of CD8+ T cells present in tissue appear to be more universally sessile and
resident (Mackay et al., 2013). This suggests that there may be more heterogeneity in
CD4+ cells in tissues, and thus more caution may be necessary when studying putative
CD4+ TRM cells to ensure that they are indeed tissue-resident.

CD4+ and CD8+ TRM cells appear to have both unique and overlapping protective
functions when they become activated in tissue. Perhaps the most obvious function for
CD8+ TRM cells is to mediate protection through direct cytotoxic killing of infected cells.
Indeed, activation of CD8+ TRM cells has been associated with expression of cytolytic
molecules perforin and granzyme in a variety of contexts (Kim et al., 1999; Masopust et
al., 2006), and in at least one case protection against brain infection has shown to be
perforin dependent (Steinbach et al., 2016). While CD4+ TRM cells are unlikely to
mediate protection through direct cytotoxicity, cytokine production has also been shown
to be critical for protection in a number of different cases (Jiang et al., 2012; Shin and
Iwasaki, 2012; Schenkel et al., 2013; Laidlaw et al., 2014; Steinbach et al., 2016), both
for CD4+ and CD8+ TRM cells. This cytokine production can lead to many different
downstream effects, including the maintenance of other protective tissue cell subsets
(Iijima and Iwasaki, 2014; Laidlaw et al., 2014), the recruitment of circulating effector T
and B cells (Schenkel et al., 2013), or the maturation of local innate cell types such as
NK cells and DCs (Schenkel, 2014; Ariotti et al., 2014). In all cases, TRM cells provide
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enhanced protection by acting in a rapid, antigen specific manner at the site of infection.
However, TRM cells are not always beneficial, and various TRM cell subsets have also
been implicated in cutaneous T cell lymphoma (Watanabe et al., 2014), psoriasis (Cheuk
et al., 2014), and asthma (Hondowicz et al., 2015).

In order to better study TRM cells, and to better define the factors involved in their
generation and maintenance, it would be useful to identify a unique, universal signature
that defines tissue residency. Unfortunately, while there appear to be some core
similarities between different TRM cell subsets, there also appears to be a significant
degree of heterogeneity. CD103 and CD69 are the most commonly used markers of
TRM cells (Masopust et al., 2001; Schön et al., 1999; Mackay et al., 2015; Teijaro et al.,
2011), but both have proven inconsistent markers (Anderson et al., 2014; Watanabe et
al., 2015). Down regulation of receptors associated with tissue egress such as CCR7,
S1P1R, and the associated transcription factor KLF-2 are more consistently associated
with TRM cells (Bromley et al., 2012; Skon et al., 2013), but these changes are not
necessarily unique to TRM cells, and can be difficult to measure. More recent global
analysis has revealed that CD8+ TRM from a variety of tissues do have an overlapping
gene signature and display a wide array of migration, adhesion, and activation markers
(Mackay et al., 2013), and may even have a common transcriptional program (Mackay et
al., 2016). However, the scope of these studies remains limited; for example they do not
examine CD4+ TRM cells at all. There are bound to be tissue and pathogen-specific
differences in different TRM cell populations, and defining these factors will be important
for studying these TRM cells.
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1.6 Delayed type hypersensitivity and skin inflammation
A delayed type hypersensitivity response (DTH) is a hallmark of protective, cell mediated
immunity against a number of different diseases such as tuberculosis, leprosy, and
leishmaniasis (Bretscher, 1992; Howard et al., 1980). Classically, this response is
thought to be associated with antigen-recognition by pathogen specific T cells, and the
response is delayed because it takes days for cells to respond and infiltrate the tissue,
leading to the associated swelling and redness. Intriguingly, two recent studies have
called into question the role of circulating T cells in the contact hypersensitivity model, a
related model of skin inflammation (Adachi et al., 2015; Gaide et al., 2015). In both
cases, TRM cells proved critical for driving the contact hypersensitivity response, while
having circulating T cells alone in the absence of TRM cells led to a delayed or otherwise
dampened response (Adachi et al., 2015; Gaide et al., 2015). Whether or not a similar
phenomenon occurs in the delayed type hypersensitivity response associated with
protection against leishmaniasis remains to be determined.

The lymphocyte infiltration associated with a DTH response is regulated by a cascade of
surface molecule adhesions between T cells expressing molecules such as VLA-4, P
and E selectin ligands, and LFA-1 and endothelial cells expressing their binding partners
in VCAM-1, P and E selectin, ICAM-1, and PECAM-1, all of which are upregulated
during inflammation (Muller, 2013; Iijima and Iwasaki, 2015). While the rules governing
T cell infiltration into inflamed tissue are reasonably well defined, it remains unclear what
processes are involved in T cell entry into uninflamed tissue, although it is evident that in
some infection models this entry does occur, resulting in the establishment of TRM cells
that are widely distributed and not confined to a local site (Masopust et al., 2001; Jiang
et al., 2012). Developing models of TRM cell formation in which there is significant
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infiltration of T cells into uninflamed sites will allow for better study of this issue, which is
important because generating TRM cells throughout tissue will likely be critical for
inducing broad protection.

1.7 Summary
The CD4+ T cell response generated during a primary leishmania infection is highly
protective against reinfection, but this response has yet to be successfully reproduced in
the absence of natural infection, suggesting some deficiency in our understanding of the
cells involved in protection.

During a primary infection (Fig. 1), antigen-specific effector

T cells are primed in the draining lymph node, proliferate, migrate to the site of infection,
and mediate protection. Concurrently, a population of long-lived CD62L+ TCM cells is
generated that can further feed into the TEff cell response. TEff and TCM cells are
maintained once infection is resolved and are important for secondary protection, but
whether or not skin-associated TRM cells might form during leishmania infection and
further augment protection is unknown. Here, we investigate the role of skin-resident
CD4+ T cells during leishmania infection. TRM cells can provide protection in a number
of different ways, so we also explore mechanisms by which leishmania TRM cells might
mediate protection (Fig. 2). The goal of these studies is to gain a better understanding
of the requirements for the generation and maintenance of the T cells involved in a
protective immune response to leishmania in the skin, with the hope that this knowledge
can be leveraged to develop better vaccines against the disease.
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Figure 1. T cell responses following infection with leishmania. Leishmania
parasites are deposited in the skin by infected sand flies and rapidly invade
phagocytic cells, including dendritic cells (DC). DCs migrate from the skin to the
draining lymph node (1) where they stimulate naïve T cells, which proliferate
and differentiate into effector T (TEff) cells (2) or central memory (TCM) cells (3).
TEff cells leave the lymph nodes and migrate to the site of infection (4), where
they produce IFNγ leading to parasite control. Some of the TEff cells may be
retained at the site of infection, or migrate to distant skin sites, where they could
become resident memory T (TRM) cells (5).
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Figure 2. Potential TRM cell responses following a secondary infection
with leishmania. During a secondary infection, TRM cells are poised to respond
rapidly. Upon activation, TRM cells could function in a number of ways including
(1) the production of cytokines, (2) the recruitment of TEff cells or (3) phagocytic
cells such as inflammatory monocytes (iMO), or (4) activating DCs to migrate
from the skin to the draining lymph node to stimulate TCM cells to become (5)
TEff cells.

CHAPTER 2: Skin Resident Memory CD4+ T Cells Enhance Protection Against
Leishmania major Infection

2.1 Abstract
Leishmaniasis causes a significant disease burden worldwide. Although Leishmaniainfected patients become refractory to reinfection following disease resolution, human
vaccines have not yet achieved effective immune protection. While circulating
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Leishmania-specific T cells are known to play a critical role in immunity, the role of
memory T cells present in peripheral tissues has not been explored. Here we identify a
population of skin-resident leishmania-specific memory CD4+ T cells. These cells
produce IFNγ, and remain resident in the skin when transplanted by skin graft onto naïve
mice. They function to recruit circulating T cells to the skin, resulting in better control of
the parasites. Our findings are the first to demonstrate that CD4+ TRM cells are
generated in response to a parasitic infection, and indicate that protective immunity to
leishmania, and thus the success of a vaccine, may depend on generating both
circulating and skin-resident memory T cells.

2.2 Introduction
The development of effective vaccines for several intracellular microbial pathogens, such
as mycobacteria, toxoplasma, plasmodium, and leishmania, remains an elusive goal.
Despite substantial efforts to define the mechanisms required for resistance, to develop
new adjuvants, and to identify protective antigens, the long-lived cellular immunity
generated in response to infection has not been recapitulated by vaccination. To
address this problem in leishmaniasis, we have focused on defining the memory T cells
that mediate infection-induced immunity.

C57BL/6 mice show robust immunity to reinfection following resolution of a primary
Leishmania major infection (referred to here as ‘immune mice’), providing a useful model
to interrogate the factors that might contribute to a successful vaccine. Previous studies
have shown that immune mice contain circulating CD4+ T cells with effector, effector
memory, and central memory phenotypes (Scott et al., 2004; Colpitts et al., 2009;
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Colpitts and Scott, 2010). Each of these T cell subsets likely plays a role in resistance to
reinfection, with the effector subsets rapidly migrating into tissues to provide protection
and central memory T cells proliferating in the draining lymph node to provide a pool of
new effector cells. However, while adoptive transfer of either effector or central memory
T cells to naïve mice enhances immunity to reinfection (Zaph et al., 2004), neither
subset alone or in combination provides the same level of protection as that seen in
intact immune animals.

In addition to circulating memory T cells, an additional memory T cell subset resides in
the tissues as resident memory T cells (TRM) (Kim et al., 1999; Masopust et al., 2001;
Hogan et al., 2001a; Clark et al., 2006; Gebhardt et al., 2009; Wakim et al., 2010;
Hofmann and Pircher, 2011; Jiang et al., 2012; Mackay et al., 2012; Schenkel et al.,
2013). Several studies have described TRM cells that mediate immunity to acute viral
infections, such as vaccinia, herpes simplex, influenza, and lymphocytic choriomeningitis
virus (Gebhardt et al., 2009; Teijaro et al., 2011; Jiang et al., 2012; Schenkel et al.,
2013). These TRM cells can be found in the gut, brain, lung, and skin (Kim et al., 1999;
Clark et al., 2006; Wakim et al., 2010; Teijaro et al., 2011), and their location allows
them to respond immediately to control a challenge infection without the delay
associated with the mobilization of circulating T cells. Additionally, TRM cells can
promote rapid recruitment of effector cells from the circulation (Schenkel et al., 2013)
and induce antigen-independent innate immunity (Schenkel et al., 2014a; Ariotti et al.,
2014), therby accelerating and amplifying resistance to infections.

CD8+ TRM cells are fairly well characterized, but less is known about CD4+ TRM cells.
Nevertheless, recent studies using Kaede-Tg mice to facilitate tracking of T cells in the
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skin indicate that a population of CD4+ T cells appear to be skin-resident under
homeostatic conditions (Bromley et al., 2012). In addition, CD4+ TRM cells in the lung
and vaginal mucosa have been reported to enhance resistance to influenza and herpes
simplex virus respectively (Hogan et al., 2001b; Teijaro et al., 2011; Iijima and Iwasaki,
2014), and a population of human tissue-resident CD4+ T cells remain in the skin after
circulating T cells have been depleted (Clark et al., 2012). However, the potential role of
CD4+ TRM cells in establishing resistance to chronic parasitic infections such as L. major
is virtually unknown.

Here we identify for the first time a tissue resident population of CD4+ T cells that seed
the skin following L. major infection. These cells are observed in skin sites distant from
the primary infection site soon after infection, and persist long term in immune mice.
They produce IFNγ in response to stimulation with L. major, and during a secondary
challenge act as sentinels to rapidly recruit circulating memory cells, resulting in
enhanced protection against reinfection. Thus, our results suggest that this previously
unidentified population of memory CD4+ T cells is instrumental in protection against
leishmania parasites and should now be considered during vaccine development.

2.3 Materials and Methods
Mice
C57BL/6 mice were purchased from the National Cancer Institute (Fredericksburg, MD).
Ifng/Thy1.1 knock-in mice were provided by Dr. Casey Weaver (University of Alabama at
Birmingham). All mice were maintained in a specific pathogen-free environment at the
University of Pennsylvania Animal Care Facility. This study was carried out in strict
accordance with the recommendations in the Guide for the Care and Use of Laboratory
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Animals of the National Institutes of Health, and the protocol was approved by the
Institutional Animal Care and Use Committee.

Parasites
L. major (Friedlin) parasites were grown in Schneider's insect medium (GIBCO)
supplemented with 20% heat-inactivated FBS, 2mM glutamine, 100 U/ml penicillin, and
100 µg/ml streptomycin. Metacyclic enriched promastigotes were used for infection
(Späth and Beverley, 2001). Mice were infected with 2 x 106 L. major in the left ear and
sacrificed 8-64 weeks after infection.

Antibodies
For flow cytometry analysis anti-CD45 AF700, anti-CD45.2 APC-eF780, anti-CD45.1
eF480, anti-CD90.2 APC, anti-CD69 FITC, anti-CD103 PE, anti-CD90.1 PE-Cy7, antiFoxP3 PE, anti-CD11b FITC (eBioscience), anti-CD4 PE TexasRed (Invitrogen), antiCD8b PerCp/Cy5.5, and anti-IFNγ PE-Cy7 (Biolegend) were used. For in vivo CD4+
depletion mice received intraperitoneal (i.p.) injections of 250 µg GK1.5 on days -5 and 2 before challenge. For intravascular staining mice were injected with 3 µg anti-CD45.2
AF780 (eBioscience) 3 minutes before they were euthanized by CO2.

Skin Preparation
For ear preparation, dorsal and ventral layers of the ear were separated and incubated
in RPMI (Gibco) with 250 µg/mL Liberase TL (Roche) for 90 minutes at 37°C in 5% CO2.
Cells within auricular skin were dissociated using a 40 µm cell strainer (BD Pharmingen)
and resuspended in RPMI media containing 10% FBS. For flank preparation, flank skin
was shaved using an electric trimmer equipped with a two-hole precision blade (Wahl)
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and treated with depilating agent (Nair) for 1 minute. A section of dermis was excised,
then minced with a sterile scalpel blade into ~2mm sections. Flank sections were
incubated in RPMI containing 250 µg/mL Liberase TL for 120 minutes with vortexing
every 30 minutes. The resulting solution was passed through a 40 µm cell strainer and
resuspended in complete RPMI (cRPMI) supplemented with 10% FBS, 100 U/ml
penicillin, 100 µg/ml streptomycin, and 55 µM 2-Mercaptoethanol.

Bone marrow derived dendritic cell (BMDC) restimulation
BMDCs were generated by culturing C57BL/6 bone marrow in GM-CSF supplemented
cRPMI for 7-11 days. BMDCs were then harvested and infected for 5-8 hours with
stationary phase L. major at a ratio of 10:1 in the presence of 1 µg/ml CpG and LPS.
Infected BMDCs were incubated at a ratio of 1:5 with 106 skin homogenate cells in 24
well plates overnight 12-16 hours, in the presence of 5 µg/ml BFA (eBioscience) for the
last 4 hours when intracellular IFNγ staining was performed. Samples were harvested,
stained with monoclonal antibodies, and data collected on an LSR cytometer.

Parasite titration
Parasite burden from ear and flank skin was calculated by serial dilution (1:10 and 1:5
respectively) in 96-well plates incubated at 26°C. The number of viable parasites was
calculated from the highest dilution at which parasites were observed 7 days into culture.

Skin grafts
Donor skin was prepared under sterile conditions from naïve and immune mouse flank
skin by shaving, depilating, cleaning with chlorhexidine (Vetoquinol), then excising the
skin using sterile instruments. 8mm biopsy punches (Miltex) were used to size donor
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grafts, which were then placed onto a graft bed generated by a 6mm biopsy punch of
mice anesthetized with isofluorene and treated with 0.1 mg/kg buprenorphine as a
preemptive analgesic. Grafts were covered with non-adherent dressing (Adaptec) and
held in place with Tegaderm (3M) wrapped circumferentially around the body of the
mouse to provide protection against loss and trauma. Mice were monitored twice daily
for the first 48 hours and daily for 7 days after grafting, given buprenorphine and
rewrapped where necessary. In challenge experiments, grafted skin was injected
intradermally with 2 x 106 metacyclic L. major 10-14 days after grafting.

Adoptive transfer
Single cell suspensions from spleen and lymph node were incubated 4 minutes at room
temperature in the presence of 2.5 µM CFSE in the dark. The reaction was quenched
with 10% FBS and resuspended at 5-10 x 107 cells/mL in PBS, then transferred
intravenously (i.v.) in 400 µL volume into recipient mice.

LCMV infection
C57BL/6 mice were injected i.p. with 2 x 105 pfu LCMV Armstrong. LCMV immune
donor mice were sacrificed at least 15 days after infection, single cell suspensions were
generated from spleen and lymph node, CFSE labeled, and transferred i.v. into recipient
mice.

Transcriptional profiling
Flank tissue sections were homogenized in RLT buffer using a rotor-stator. RNA was
isolated using the RNeasy Plus kit (Qiagen). Biotin-labeled complementary RNA (cRNA)
was generated using the TargetAmp-Nano amplification kit (Epicentre). RNA and cRNA
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quality were assessed on a BioAnalyzer (Agilent). MouseRef-8 v2.0 Expression
BeadChips (Illumina) were then hybridized with cRNA from 4 immune and 4 naïve mice
challenged in the flank with L. major. Analysis was performed using the statistical
computing environment R (v3.0.2), with RStudio and Bioconductor suite packages
(v0.97; Boston, MA). Data have been deposited on the GEO database for public access
(GSE# pending). GSEA (Subramanian et al., 2005) was performed with the Broad
Institute's MSigDB (v4.0) to query the "C2: Canonical Pathways" collection, which
contains 1320 gene sets.

Statistical analysis
Statistical analysis was performed with the Mann-Whitney test (two-sided t-test, paired
or unpaired where applicable) in Prism software (GraphPad).

2.4 Results
L. major specific CD4+ T cells are present in skin distal from the primary infection
site

C57BL/6 mice infected with L. major in the ear develop a lesion that resolves by 12
weeks. These mice are resistant to reinfection, and are referred to as immune mice. To
determine if leishmania-specific T cells were present in skin sites distant from the
primary infection site, we isolated cells from the uninfected ear (contralateral ear) and
the flank. We also isolated cells from the primary infection site (primary ear) of immune
mice, and from the ears and flank of naïve mice. The cells were incubated with or
without L. major infected dendritic cells overnight and IFNγ production assessed as a
measure of T cell activation. We utilized Ifng/Thy1.1 knock-in mice in these experiments
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(Harrington et al., 2008) so that we could use surface staining for Thy1.1 to sensitively
detect transcription of the IFNγ gene. As expected, leishmania-responsive cells were
absent in ear and flank skin from naïve mice, while approximately 25% of CD4+ T cells
from the primary ear of immune mice produced IFNγ in the presence of L. major infected
DCs, likely due to a low level of persistent infection (Fig. 1A, Fig 1B). However, when
we stimulated cells from two uninfected sites of immune mice, the contralateral ear and
the flank skin, we also detected a population of CD4+ T cells that responded to L. major
infected DCs (Fig. 1A, Fig 1B). These cells did not respond to uninfected DCs,
demonstrating their specificity. In separate experiments, we used intracellular staining to
confirm the production of IFNγ protein (Fig. 1C). A similar population of IFNγ responsive
CD4+ T cells in immune mice was also recently observed (Peters et al., 2014).
Importantly, after lesion resolution, no parasites could be detected in either the
contralateral ear or the flank skin by culture, qRT-PCR for ribosomal RNA, or PCR for
kinetoplast DNA (data not shown).
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Figure 1. L. major-specific CD4+ T cells are present in skin distant from
the primary infection site. Skin was collected from either naïve C57BL/6 mice
(wild-type or IFNγ-reporter mice) or mice that had been previously infected with
L. major in the left ear and resolved their lesions (referred to as immune mice).
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Skin isolated from infected mice included the left ear (primary ear), contralateral
ear (CL), and immune (Imm.) flank; skin from naïve mice (N.) included the ear
and the flank. (A-C) Cells from the skin were incubated with either uninfected
bone-marrow derived dendritic cells (DC) or BMDC that were infected with L.
major (iDC), and 12 hours later IFNγ production in CD4+ T cells (gated on live,
CD45, CD90.2, CD4 cells) was assessed by expression of Thy1.1 (A, B) or by
IFNγ intracellular staining (C). (A) Representative flow plots. (B, C) Each dot
represents an individual mouse, and data are combined from at least 3
experiments. (D) FITC anti-CD45.2 antibody was injected iv into immune mice
(15 wks post-infection) and 3 minutes later blood, flank, primary ear (Prim.) and
contralateral (CL) ear were collected and incubated with infected BMDCs as
above, and FITC staining assessed on CD4+ IFNγ+ cells. Data shown are from
one representative experiment of 2 (n = 5 mice). (E) Cells isolated from the
flank or spleen of immune mice were incubated with L. major infected BMDCs
as above, and each bar represents the mean (+ SEM) percent IFNγ producing
CD4+ T cells detected by flow cytometry (gated on live, CD45, CD4 cells).
Data shown are combined from 3 experiments (n = 10 mice per group). *, P <
0.05; **, P < 0.01; *** P < 0.001.

To determine if the leishmania-responsive cells we observed in the contralateral ear and
flank of immune mice might be in the vasculature of the skin, we used a technique
developed to distinguish resident and circulating T cells in tissues (Anderson et al.,
2012). Immune mice were injected with FITC anti-CD45.2 antibody intravenously, and 3
minutes later the blood and skin were collected and assessed for responsiveness to L.
major-infected dendritic cells. The IFNγ+ cells from the blood were FITC+, while cells
from the skin were not, indicating that the leishmania-responsive cells were indeed
contained within the skin, sequestered from circulation (Fig. 1D). Consistent with the
potential for these cells to be resident in the skin, we found that >80% of the leishmaniaresponsive cells in the contralateral ear and flank were CD69+ and all of the cells were
CCR7- (data not shown). Finally, when we compared the frequency of leishmaniaresponsive cells in the skin to the spleen, we found a significant enrichment in the skin,
suggesting that there may be preferential retention of these cells in the tissue (Fig. 1E).
Together, our results identify a previously unrecognized population of T cells distributed
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broadly throughout the skin, positioned to act as a frontline defense against leishmania
infection.

Leishmania-specific CD4+ T cells are resident in immune skin

To determine how long after infection L. major-specific CD4+ T cells could be detected in
skin distant from the primary infection site, we incubated infected DCs with skin cells
from immune mice at various time points after infection. L. major-specific CD4+ T cells
persisted in skin sites distant from the primary infection site at every time point we
observed, up to one year after resolution of disease (Fig. 2A). While these data
confirmed that L. major-responsive CD4+ T cells are a persistent population in the skin,
they did not distinguish whether these T cells were resident in skin or were instead being
replenished from circulation.

To address this issue, we grafted uninfected flank skin from immune CD45.2 mice
originally infected in the ear onto naïve CD45.1 recipients, and determined how long
donor L. major-specific T cells remained in the grafts by quantifying the number of
leishmania memory cells present within donor skin at the time of grafting (t = 0), and in
harvested grafts 1, 2, and 4 weeks later. At all time points we were able to identify L.
major-specific donor cells resident within the graft skin (Fig. 2B). The difference
between the number of L. major-specific cells at the time of grafting and later time points
was not significant but did trend towards a decrease, suggesting that some cells might
recirculate as well. Regardless, leishmania-responsive CD4+ T cells were retained for at
least 4 weeks in immune skin in the absence of circulating memory cells, and thus form
a tissue-resident population.
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Figure 2. Leishmania-specific CD4+ T cells are resident in immune skin.
(A) Flank skin was collected from naïve or immune mice at various time points
after L. major infection, and IFNγ producing CD4+ T cells detected as in Fig. 1.
Data shown represents the mean (+ SEM) percent IFNγ producing CD4+ T
cells detected by flow cytometry (n= 3-4 mice per time point). (B) Flank skin
from immune mice (13-14 weeks post-infection) was grafted onto naïve mice,
and at various times the grafts were harvested and IFNγ producing CD4+ T
cells detected as in Fig. 1. Quantification of L. major-specific cells in skin grafts
before grafting (time 0) and 1, 2, or 4 weeks later is shown. Data are combined
from two separate experiments and each dot represents one mouse. *, P <
0.05.

L. major immune mice rapidly upregulate interferon and chemokine signaling
following L. major challenge

To determine if L. major-specific TRM cells could contribute to the immune response early
after a challenge infection, we injected previously uninfected flank skin from naïve and
immune mice with L. major, harvested the inoculated skin 12 hours later, and compared
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gene transcript levels. We found 145 differentially regulated genes between naïve and
immune skin (fold change ≥ 2, false discovery rate ≤ 0.05) (Fig. 3A). Strikingly,
competitive gene set enrichment analysis revealed interferon signaling to be the most
highly upregulated canonical signaling pathway in immune mice (Fig. 3B). Chemokine
and chemokine receptor signaling were also among the most significantly enhanced
gene sets (Fig. 3C).

To confirm that the transcriptional changes we observed were due to cells resident in
immune skin and independent of any cells that might have been recruited, we isolated
flank skin cells and incubated them with L. major in vitro. We assessed the
transcriptional response of a select group of genes found to be upregulated by global
transcriptional profiling using qRT-PCR and observed a significant increase in
expression of several IFNγ responsive genes (Fig. 3D). Notably, CXCL9 and CXCL10
were highly expressed in restimulated flank skin both in vitro and in vivo. These two
chemokines interact with CXCR3 on activated T cells to drive T cell recruitment
(Nakanishi et al., 2009). These data, along with recent evidence in the literature,
(Schenkel et al., 2013; Ariotti et al., 2014) led us to hypothesize that L. major-specific
TRM cells might function by activating a program to rapidly recruit circulating effector T
cells to the site of infection after challenge.
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Figure 3. L. major immune mice rapidly upregulate interferon and
chemokine signaling following challenge. Naïve or immune mice (20 wk
post-infection) were infected in the flank with L. major, and the flank skin
harvested 12 hours later for transcriptional profiling by microarray. (A) Heat
map of 145 differentially expressed genes between 4 naïve and 4 immune mice
challenged in the flank (fold change ≥ 2, false discovery rate ≤ .05). (B, C) Gene
set enrichment analysis plot for gene sets "interferon signaling" (B) and
"chemokines and chemokine receptors" (C). Heat maps show the top
upregulated genes from the interferon-signaling gene set or chemokines and
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chemokine receptors gene set between naïve and immune mice (red = high,
blue = low). Normalized enrichment score (NES) with false discovery rate qvalue as calculated by GSEA. (D) Cells were isolated from the flank skin of
immune mice (20 weeks post-infection) were incubated with or without L. major
parasites for 12 hours and gene expression assessed by qRT-PCR. Data
shown are the fold induction of IFN-regulated genes following exposure to L.
major. Each dot represents an individual animal, and is from one representative
experiment of 2. *, P < 0.05.

Leishmania TRM cells enhance T cell recruitment following L. major challenge

To compare the recruitment of effector T cells to an L. major challenge site with and
without leishmania-specific TRM cells, we transferred CFSE-labeled splenocytes from
immune mice into naïve or immune recipients, infected the flank skin, and measured the
number of cells recruited from the blood to the challenge site 20 hours later. Although
equivalent pools of circulating cells were available in the blood of naïve and immune
recipients, there was significantly enhanced recruitment of both CD4+ and CD8+ T cells
to the skin of leishmania-immune animals (Fig. 4A, 4B). Increased recruitment was not
a response to tissue injury alone, as PBS injection was insufficient to increase
recruitment in immune animals compared with naïve mice (Fig. 4C).
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Figure 4. L. major-specific TRM cells enhance T cell recruitment following
challenge with L. major. Splenocytes from L. major (A, B, C) or LCMV (D)
immune mice were CFSE labeled to track them following transfer and were
injected i.v. into either naïve or L. major immune mice (20 weeks post-infection)
that were then challenged with L. major or PBS in the flank. Recruitment of cells
to the challenge site was assessed 20 hrs later. (A) Representative flow plots of
CFSE+ CD4+ T cells comparing the blood and the flank in naïve or immune
mice challenged with L. major. (B) Frequency and number of transferred L.
major immune CD4+ and CD8+ T cells in the blood and flank skin of naïve and
immune mice 20 hours after challenge with L. major. (C) Frequency and
number of transferred L. major immune CD4+ T cells 20 hours after challenge
with L. major or injection of PBS in naïve or immune mice. (D) Frequency and
number of transferred LCMV immune lymphocytes in the blood and flank skin of
naïve and immune mice 20 hours after challenge with L. major. (E) L. major
immune mice were treated with anti-CD4 mAb, and the frequency of CD4+ T
cells in the skin of untreated or anti-CD4 treated immune mice is shown. (F, G)
Naïve, L. major immune or L. major immune mice treated with anti-CD4 mAb
(F) or anti-CXCR3 mAb (G) received CFSE-labeled splenocytes from immune
mice, and were then infected in the flank with L. major. After 20 hr the
frequency and number of the transferred cells in the blood and flank was
determined. (H,I) Flank skin from naïve or immune mice was grafted onto the
flank of naïve mice. After 7 days the recipient mice were injected intravenously
(i.v.) with CFSE-labeled immune cells, each graft was infected with L. major
and 20 hrs later cells isolated from the grafts. (H) Representative flow plots of
CFSE+ CD4+ T cells comparing the blood and naïve or immune skin grafts
challenged with L. major. (I) Frequency and number of transferred L. major
immune CD4+ T cells in naïve or immune skin grafts (cells were gated on live,
CD45, CD90.2, CD4 cells). All data are from one representative experiment of
two or more with 3 or more mice per experiment, and each bar represents the
mean (+ SEM) of individual mice (A-G) or combined data from two experiments
where each dot represents a mouse (H, I). Immune mice used in all these
experiments were 14 to 20 weeks post-infection. *, P < 0.05; **, P < 0.01; ***, P
< 0.001.

While the activation of leishmania TRM cells appeared to be antigen-specific, we
hypothesized that after antigen recognition these TRM cells could recruit any circulating
memory T cell (Schenkel et al., 2013). Indeed, when we transferred LCMV immune T
cells to naïve and L. major immune mice, we also observed increased recruitment of T
cells to immune skin following challenge (Fig 4D). Thus, these results show that antigenspecific stimulation of immune skin can promote increased recruitment of circulating
memory T cells non-specifically.
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To determine if T cell recruitment was dependent on the CD4+ T cells in the immune
skin we compared the recruitment of transferred memory cells to immune and CD4+ T
cell-depleted immune mice. CD4+ T cells were depleted from both the recipient and
donor cell populations, so we focused on the recruitment of CD8+ T cells for these
studies. Following anti-CD4 mAb treatment, no CD4+ T cells could be identified in the
skin of immune mice (Fig 4E), and the enhanced recruitment of circulating memory cells
observed in L. major immune skin was absent in anti-CD4 mAb treated mice, suggesting
that the enhanced recruitment was CD4+ T cell dependent (Fig 4F).

We next assessed the role of chemokines in promoting the T cell recruitment to
challenge sites by treating immune mice with anti-CXCR3 mAb. The chemokine
receptor CXCR3 interacts with CXCL9, CXCL10, and CXCL11, and anti-CXCR3 mAb
blocks CXCL10 and CXCL11 signaling in vitro (Uppaluri et al., 2008). We transferred
labeled L. major-immune cells to intact and anti-CXCR3 mAb treated immune mice,
challenged in the flank skin, and compared the recruitment of T cells to the challenge
site 20 hours later. The increase in recruitment to immune flank skin was completely
blocked in anti-CXCR3 mAb treated mice, indicating that this chemokine axis indeed
promotes the enhanced T cell recruitment seen in immune mice (Fig 4G).

Finally, to determine if skin-resident cells were sufficient to drive the increased
recruitment of activated T cells to immune skin, we grafted naïve and immune flank skin
in parallel onto opposite sides of naïve recipients that lack any L. major memory cells.
We then transferred circulating L. major immune cells, challenged both the naïve and
immune graft with L. major, and compared recruitment of the labeled cells 20 hours later.
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We observed enhanced recruitment of circulating cells to the immune graft compared to
the naïve graft, indicating that cells from the skin alone could indeed mediate this effect
(Fig. 4H, Fig. 4I). Together, these data indicate that L. major-responsive CD4+ T cells in
the skin promote the early recruitment of circulating effector cells, and thus have the
potential to improve the outcome of a secondary infection.

Leishmania-specific TRM cells provide increased protection against secondary
challenge

Finally, we sought to determine if TRM cells could contribute to the control of L. major
infection in immune mice. To specifically assess the effects of TRM cells in the absence
of circulating memory T cells, we grafted both naïve and immune skin onto a naïve
recipient and challenged both skin grafts. After two weeks, we compared the parasite
burden in each graft and found no significant difference between naïve and immune
grafts (Fig. 5A). Thus TRM cells did not appear to provide a significant level of protection
by themselves. To assess if TRM cell driven recruitment of circulating cells was
important, we grafted naïve mice with both naïve and immune skin as before, but in
addition we adoptively transferred L. major-specific memory cells isolated from immune
mice. As expected, the presence of circulating L. major-specific cells significantly
reduced the parasite burden even in the naïve graft two weeks post infection (Fig. 5A).
However, the parasite burden in the immune graft was further significantly decreased
compared to the naïve graft, indicating that immune skin was indeed better protected.

34

Figure 5. L. major-specific TRM cells provide increased protection against
secondary challenge. Flank skin from naïve or immune mice was grafted onto
the flank of naïve mice. After 7 or 30 days, grafts from both the naïve and
immune mice were challenged with L. major and two weeks later the grafts
were isolated and parasite burdens measured. Some mice received 20 x 106
splenocytes (i.v.) from L. major immune mice at the time of challenge. (A) Naïve
or immune skin grafts in the presence or absence of adoptively transferred L.
major immune cells were challenged with L. major and the parasite burden was
assessed at 2 weeks. Data shown are the mean (+ SEM) parasite burden. (B)
Intact naïve or immune mice, or naïve and immune skin grafted onto naïve mice
were challenged with L. major. The mice with skin grafts also received L. major
immune cells as above and the parasite burden was assessed at 2 weeks. The
data shown are the mean (+ SEM) of the parasite burden. (C) Naïve or immune
skin was grafted onto naïve mice, and 30 days later mice received L. major
immune cells as above and both grafts were challenged with L. major. The data
shown are the mean (+ SEM) of the parasite burden 2 weeks after L. major
challenge. Data from A and B are representative of 2 experiments (n = 5 mice
per group), and C is combined data from 2 experiments (n = 6 mice). Immune
mice used in all these experiments were 14 to 20 weeks post-infection. *, P <
0.05.

To assess the level of protection achieved by transferring both circulating and skinresident immune cells to naïve mice, we compared skin-grafted mice to intact immune
mice 2 weeks after L. major challenge in the flank (Fig. 5B). As expected, intact immune
mice were significantly protected compared to naïve mice, and were also better
protected than naïve graft skin that had access to circulating cells alone. However, there
was no difference between the level of protection observed in intact immune mice and
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skin-grafted mice challenged in immune flank skin, suggesting that the presence of
circulating and skin-resident T cells was sufficient for optimal protection.

Finally, to confirm that this protective phenotype was long lived, we grafted naïve and
immune skin onto naïve mice allowed 30 days for the grafts to heal and revascularize.
We then transferred in L. major immune cells, challenged each graft, and compared
parasite burdens at 2 weeks. Even one month after grafting, the parasite burdens were
significantly lower in immune skin, suggesting that L. major-specific TRM cells were still
mediating protective effects (Fig 5C). Together, these data support a model in which
leishmania TRM cells act as sentinels in the skin to rapidly recruit circulating memory cells
and restrict parasite replication. Consequently, immunizations that do not induce
leishmania TRM cells may result in delayed recruitment of effector cells and impaired
control of infection.

2.5 Discussion
We discovered that tissue-resident memory CD4+ T cells are present in the skin after
resolution of leishmania infection. While resident memory T cells generated in response
to acute viral infections have been extensively studied (Kim et al., 1999; Hogan et al.,
2001a; Gebhardt et al., 2009; Wakim et al., 2010; Jiang et al., 2012; Schenkel et al.,
2013; Teijaro et al., 2011; Iijima and Iwasaki, 2014), we identify for the first time a
population of skin-resident CD4+ T cells that form in response to a chronic parasitic
infection. These TRM cells persist in the absence of circulating leishmania-specific T
cells, are retained long after resolution of disease, produce IFNγ, and enhance the
recruitment of circulating memory cells to the site of leishmania challenge. This rapid
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mobilization of pathogen specific T cells significantly reduced the parasite burden,
indicating that CD4+ TRM cells contribute to protective immunity to leishmania.

While several subsets of leishmania-specific T cells are present in mice that have
resolved a primary infection, adoptive transfer of these cells into naïve mice never
recapitulates the level of protection seen in intact immune mice. Such results could
stem from an inability to adoptively transfer adequate numbers of leishmania-specific T
cells, however our current results documenting the ability of skin-resident leishmania
memory cells to rapidly recruit circulating effector cells to the site of infection support an
alternative hypothesis: that the absence of TRM cells in recipient mice is responsible for
the lower level of observed protection. Nevertheless, our results also show that these
TRM cells are insufficient to mediate protection alone, and require a circulating pool of
leishmania-specific CD4+ T cells. These circulating cells have been well-characterized,
and include effector (CD62Llo, IL-7Rlo), effector memory (CD62Llo, IL-7Rhi), or central
memory (CD62Lhi, IL-7Rhi) CD4+ T cells (Colpitts et al., 2009; Colpitts and Scott, 2010).
Most recently, the circulating leishmania-specific T cells have been further characterized,
and the most protective cells were shown to be Ly6C+ CD4+ effector T cells (Peters et
al., 2014). Taken together, our data indicate that an optimal vaccine would need to
generate both circulating protective CD4+ T cells and TRM cells.

An important attribute of the leishmania-specific CD4+ TRM cells is their persistence in
the absence of chronic parasites. Specifically, leishmania-specific skin-resident memory
T cells transferred by skin graft to uninfected mice persist for several weeks. This is in
contrast to effector cells, which depend on low numbers of persisting parasites to be
maintained (Belkaid et al., 2002a), and is most likely why optimal protection requires
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chronic infection (Uzonna et al., 2001; Belkaid et al., 2002a; Sacks, 2014; Mendez et al.,
2004). Nevertheless, some protection can be maintained in the absence of persisting
parasites, which we previously attributed to the parasite-independent maintenance of
central memory T cells (Zaph et al., 2004). Our discovery that CD4+ TRM cells are
maintained in skin in the absence of persistent parasites now identifies another parasiteindependent memory T cell population that is an ideal target for a T cell vaccine.

The CD4+ TRM cells that we identified in leishmania-infected mice appear to function by
recruiting circulating effector cells. Transcriptional profiling of immune skin challenged
with L. major showed increased expression of many IFNγ/STAT1 dependent genes,
including the IFNγ inducible chemokines CXCL9 and CXCL10. By blocking the receptor
for these chemokines CXCR3, we demonstrate that chemokine receptor signaling is
important for the enhanced recruitment to challenge sites in immune mice. Although a
similar role for CD8+ TRM cells has been described (Schenkel et al., 2013; Ariotti et al.,
2014), other studies suggest that CD8+ TRM cells can control viruses by themselves,
even when the recruitment of circulating cells is suppressed by treatment of mice with
FTY-720 (Hofmann and Pircher, 2011; Jiang et al., 2012). This was not the case in
leishmania infection, which might be due to inherent differences between CD4+ and
CD8+ TRM cells, or more likely might be related to the nature of the pathogen. Unlike
acute viral infections that are quickly controlled even in naïve hosts, leishmaniasis is a
chronic disease that takes months to heal, suggesting that rapid control of secondary
challenges may require a particularly strong immune response. Thus, while leishmaniaspecific TRM cells are an important component in the protection seen in immune mice,
they also require the presence of circulating immune cells to promote protection.
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Multiple strategies have been applied to leishmania vaccine development, including the
use of different live or killed parasites, various adjuvants, and a multitude of DNA
constructs and protein subunits (Coler and Reed, 2005; Kedzierski et al., 2006; Dunning,
2009). While some of these have provided a degree of protection (Palatnik-de-Sousa,
2012), there still is no human vaccine against leishmania (Noazin et al., 2008), and none
of the experimental vaccines induce the level of protection seen in immune mice. Our
results provide a new model for how leishmanial infections generate resistance to
reinfection, one in which both circulating and tissue-resident cells work together to
provide robust protective immunity. Taking this into account, new approaches to the
development of a vaccine will need to consider not only the generation of circulating
memory T cells, but also how best to generate a population of TRM cells, which may be
the missing link in the quest for a successful leishmania vaccine.

CHAPTER 3: Skin Resident CD4+ T cells Protect Against Leishmania major by
Recruiting and Activating Inflammatory Monocytes
3.1 Abstract
Tissue-resident memory T cells are required for establishing protective immunity against
a variety of different pathogens, although the mechanisms mediating protection by CD4+
resident memory T cells are still being defined. In this study we addressed this issue
with a population of protective skin-resident, IFNγ-producing CD4+ memory T cells
generated following Leishmania major infection. We previously found that resident
memory T cells recruit circulating effector T cells to enhance immunity. Here we show
that resident memory CD4+ T cells mediate the delayed-hypersensitivity response
observed in immune mice and provide protection without circulating T cells. This
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protection occurs rapidly after challenge, and requires the recruitment and activation of
inflammatory monocytes, which limit parasites by production of both reactive oxygen
species and nitric oxide. Overall, these data highlight a novel role for tissue-resident
memory cells in recruiting and activating inflammatory monocytes, and underscore the
central role that skin-resident T cells play in immunity to cutaneous leishmaniasis.

3.2 Introduction
Tissue-resident memory T cells (TRM) are critical mediators of immunity against a
number of different infections in a variety of different tissues (Jiang et al., 2012;
Gebhardt et al., 2009; Iijima and Iwasaki, 2014; Laidlaw et al., 2014; Teijaro et al., 2011;
Schenkel et al., 2014a; Masopust et al., 2010; Mackay et al., 2012; Cauley et al., 2002;
Wakim et al., 2012; Sakai et al., 2014). Because they are typically located at barrier
surfaces and therefore occupy the initial sites of infection, TRM cells are poised to provide
rapid protection. CD8+ TRM cells are the best defined tissue-resident T cells, and
mediate protection through direct cytotoxicity (Kim et al., 1999; Masopust et al., 2006;
Steinbach et al., 2016), production of cytokines (Jiang et al., 2012; Schenkel et al.,
2013), maturation of local innate cells (Schenkel et al., 2014a), triggering of tissue-wide
antiviral signaling (Ariotti et al., 2014), and/or the recruitment of additional lymphocytes
to the site of infection (Schenkel et al., 2013). CD4+ TRM cells remain relatively
uncharacterized, although they have been described in the lung, vaginal mucosa, and
skin (Iijima and Iwasaki, 2014; Teijaro et al., 2011; Laidlaw et al., 2014; Collins et al.,
2016). We recently demonstrated that skin-resident CD4+ T cells play a critical role in
immunity to cutaneous leishmaniasis (Glennie et al., 2015), however the various
mechanisms by which CD4+ TRM cells mediate protection in the skin remain ill-defined.
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Human cutaneous leishmaniasis encompasses a spectrum of diseases caused by the
intracellular protozoan parasites. Murine models that mimic aspects of the human
disease have proven invaluable for understanding the mechanisms mediating
susceptibility and resistance (Scott and Novais, 2016). For example, similar to some
forms of human cutaneous leishmaniasis, C57BL/6 mice infected with Leishmania major
develop lesions that heal over several weeks, and once resolved the mice exhibit
immunity to reinfection (Scott and Novais, 2016). Studies in this model have shown that
in a primary leishmania infection, innate cells including neutrophils, monocytes, and
dendritic cells are rapidly recruited to the site of challenge (Peters et al., 2008;
Goncalves et al., 2011; Ng et al., 2008; Ribeiro-gomes et al., 2012). These cells have
the potential to restrict parasite infection (Strauss-Ayali et al., 2007; Goncalves et al.,
2011; Olekhnovitch et al., 2014; Novais et al., 2009), but they can also be co-opted by
the parasites to evade immune detection or suppress the immune response (Peters et
al., 2008; Afonso et al., 2008; van Zandbergen et al., 2004). Conversely, in a secondary
infection, the recruitment of pre-existing circulating effector CD4+ Th1 cells leads to the
rapid control of the parasites (Peters et al., 2014; Zaph et al., 2004), and CD4+ TRM cells
contribute by promoting the recruitment of these effector T cells to the site of infection
(Glennie et al., 2015). However, given their location at the site of a challenge infection
and their rapid production of IFNγ, it might be expected that CD4+ TRM cells may also
provide some level of rapid protection that is independent of additional T cell recruitment
from the blood.

Here we show that CD4+ TRM cells mediate control of the parasite burden within the first
three days of infection, which correlates with a strong delayed-type hypersensitivity
(DTH) response, the hallmark of immunity in murine and human leishmaniasis. While
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IFNγ produced by TRM cells might be expected to activate resident macrophages in the
skin and limit the parasite burden, surprisingly we found that protection by CD4+ TRM
cells required the recruitment of inflammatory monocytes that subsequently controlled
the parasites by the induction of both reactive oxygen species (ROS) and inducible nitric
oxide synthase (iNOS). Importantly, we found that TRM cells provided protection
independently of circulating CD4+ T cells, emphasizing the importance of generating TRM
cells for optimal immunity to leishmaniasis.

3.3 Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use Committee, University
of Pennsylvania Animal Welfare Assurance Number 805186.

Mice
C57BL/6 mice were purchased from the National Cancer Institute (Fredericksburg, MD).
CCR2-/- (B6.129S4-Ccr2 tm1Ifc/J), Phox-/- (B6.129S-Cybb tm1Din/J), iNOS-/(B6.129P2-Nos2 tm1Lau/J), and RAG-/- (B6.129S7-Rag1 tm1Mom/J) mice were
purchased from The Jackson Laboratory. All mice were maintained in a specific
pathogen-free environment at the University of Pennsylvania Animal Care Facility.

Parasites
L. major (Friedlin) or dsRed+ L. major (Friedlin) parasites were grown in complete
Schneider's insect medium (GIBCO) supplemented with 20% heat-inactivated FBS,
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2mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 50 µg/mL G418 sulfate
(Cellgro) (CSM). Metacyclic enriched promastigotes were used for infection (Späth and
Beverley, 2001). Mice were infected with 2 x 106 L. major or 103 L. major intradermally
in the ear or flank skin as noted.

Antibodies and treatments
For flow cytometry analysis αCD45 APC-eF780, αCD45.2 FITC, αCD45.1PE-Cy7,
αCD90.2 BV605, αCD11b BV650, αCD4 PE TexasRed, αCD8b PerCp/Cy5.5, αLy6C
AF700, αLy6G PacBlue, αMerTK APC, αCD64 PE-Cy7, αCD11c FITC, αMHCII APC,
αAF488 iNOS were incubated with single cell suspensions 30 minutes at 4°C and read
on LSR Fortessa. For ROS stain, 2ng/mL dihydrorhodamine 123 (DHR, Cayman
Chemical) was added directly ex vivo, then incubated 30 minutes at 37°C for 30 minutes.
For in vivo blockade/depletion 250 µg of αCD4 (GK1.5), αCD8 (53-6.72), αCXCR3
(CXCR3-173), 500 µg of αGR1 (RB6-8C5), αLy6G (1A8) (BioXcell), or 1 mg/kg FTY-720
(Cayman Chemical) were given i.p. one day prior to L. major challenge.

Skin Preparation
For ear preparation, dorsal and ventral cutaneous layers of the ear were separated and
incubated in RPMI (Gibco) with 250 µg/mL Liberase TL (Roche) for 90 minutes at 37°C
in 5% CO2. Cells from the skin were then dissociated using a 40 µm cell strainer (BD
Pharmingen) and resuspended in complete RPMI media (cRPMI) containing 10% FBS,
100 U/ml penicillin, 100 µg/ml streptomycin, and 55 µM 2-Mercaptoethanol. For flank
skin preparation, a section of skin was harvested from the flank following hair removal
with an electric trimmer equipped with a two-hole precision blade (Wahl). Skin sections
were then minced with a sterile scalpel blade into ~2mm sections, and incubated in
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RPMI containing 1 mg each of type III and type IV collagenase (Worthington) for 120
minutes with vortexing every 30 minutes. The resulting solution was passed through a
40 µm cell strainer and resuspended in cRPMI. Bone marrow derived dendritic cells for
restimulations were generated by culturing C57BL/6 bone marrow in GM-CSF
supplemented cRPMI for 7-11 days. BMDCs were then harvested and infected 5-8
hours with stationary phase L. major at a ratio of 10:1 in the presence of 1 µg/ml CpG
and LPS. Infected BMDCs were incubated at a ratio of 1:5 with 106 skin cells in 24 well
plates for 12-16 hours. Cells were incubated for the last 4 hours with 5 µg/ml BFA
(eBioscience), stained for IFNγ, and analyzed by flow cytometry.

Parasite quantification
Parasite burden from ear and flank skin was calculated by serial 2-fold dilution in 96-well
plates of CSM and incubated at 26°C. The number of viable parasites was calculated
from the highest dilution at which parasites were observed 7 days into culture. For
qPCR, single cell suspensions from infected tissue were diluted in RLT lysis buffer, then
RNA was isolated using the RNeasy Plus kit (Qiagen). RNA was converted to cDNA
using the High Capacity RNA to cDNA kit (Applied Biosciences), then the Power SYBR
green PCR mater mix (Applied Biosciences) was used to quantify parasite ssRNA on the
ViiA7 qPCR machine (Applied Biosciences) with primers F: 5'-TACTGGGGCGTCAGAG3' and R: 5'-GGGTGTCATCGTTTGC-3'. Cytospins were prepared at 1000 RPM
(Shandon Cytospin3) and imaged by light microscopy at 40X magnification (Nikon
E600).

Skin grafts
Skin grafts were performed as previously described (Glennie et al., 2015). Briefly, donor
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skin was prepared under sterile conditions from naïve and immune mouse flank skin by
shaving, depilating, cleaning with chlorhexidine (Vetoquinol), then excising the skin using
sterile 8mm biopsy punches (Miltex). Grafts were placed onto a fresh graft bed prepared
by excising skin using a 6mm biopsy punch. All mice were anesthetized, received
analgesics, and were monitored post-operatively as previously described. In challenge
experiments, graft skin was injected intradermally with 2 x 106 metacyclic L. major 14-20
days after grafting.

Parabiosis
Congenically disparate mice were co-housed 2 weeks prior to surgery. After induction of
anesthesia with isoflorane, each received 0.1mg/kg buprenorphine subcutaneously (s.q.)
as preemptive analgesia. The surgical site was shaved and aseptically prepared with
chlorhexidine scrub. A longitudinal skin incision was made on the mirroring side in each
mouse starting at 0.5 cm above the elbow and ending 0.5 cm below the knee joint. The
left elbow and knee of one animal were attached to the right elbow and knee of the other
parabiont with a 3-0 ethilon suture (Ethicon) around each joint beneath the skin in a
manner loose enough to not disrupt circulation to the distal limb. The dorsal and ventral
skin edges created by the flank incision from one mouse were sutured to the respective
skin edges of the second mouse using a continuous absorbable 5-0 vicryl suture patter
(Ethicon). Suture glue (Abbott laboratories) was used to approximate skin edges. 0.5
ml of 0.9% NaCl was administered s.q. to each mouse to prevent dehydration in the
immediate post-operative recovery period, and mice were monitored twice daily for the
first 48 hrs post-operatively, then observed daily for signs of surgical site complications,
pain, or discomfort. In challenge experiments, ears were infected with 2 x 106 metacyclic
L. major by intradermal injection14-20 days after surgery.
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Statistical analysis
Statistical analysis was performed with the Student’s T test (two-sided t-test, paired or
unpaired where applicable), ANOVA, or 2-way ANOVA in Prism software (GraphPad).

3.4 Results
L. major immune mice are protected within 72 hours of challenge in a CD4+ TRM
cell dependent manner
In experimental models of cutaneous leishmaniasis, protection to a challenge infection is
often assessed after several weeks, when a large difference in parasite number is
evident between naïve and immune mice. This approach also allows for the assessment
of protection mediated not only by circulating effector T cells, but also by central memory
T cells that are delayed in their protective response (Zaph et al., 2004). However, the
identification of TRM cells and their occupation of the skin led us to hypothesize that they
might contribute to immune protection very early after challenge. To test this, we
challenged naïve and leishmania-immune mice in the ear with L. major, and assessed
the immune response during the first 72 hrs of infection. For these studies, immune
mice were infected with L. major in the contralateral ear at least 12 weeks earlier, and
had resolved their primary lesion.

One of the hallmarks of immunity to leishmaniasis is the presence of a DTH response,
and a positive reaction indicates that an individual has generated a type 1 immune
response. As expected, immune mice developed a DTH response, represented by an
increase in ear swelling within 24-72 hrs after challenge, while naïve mice did not (Fig.
1A). In order to evaluate whether the presence of this DTH reaction was associated with
control of the challenge inoculum, we assessed the parasite burden by performing three
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different assays: limiting dilution, qPCR for parasite ribosomal RNA, and analysis of the
frequency of cells infected with dsRed expressing parasites by flow cytometry. We
found that the number of parasites was consistently decreased 2-4 fold in immune mice
at 72 hrs, as measured by limiting dilution and qPCR (Fig. 1B, 1C), and that the
frequency of infected cells was significantly decreased by flow cytometry (Fig. 1D).
These results demonstrate that as early as 72 hrs after challenge, mice that have
resolved a previous L. major infection can mount an immune response that is effective at
controlling the parasites.
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Figure 1. L. major immune mice are protected within 72 hrs of challenge
in a CD4+ TRM dependent manner. A) Naïve and immune mice were
challenged intradermally in the ear with 2x106 dsRed L. major and DTH
response was monitored over the course of 3 days. (B-D) Representative
parasite burden in naïve and immune mice 72 hrs after challenge as measured
by limiting dilution (B), quantitative PCR (C), or flow cytometry (D).
Representative data shown are from one experiment representative of eight (n
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= 3-4 mice per group). E) Naïve, immune, and immune mice depleted of CD4+
or CD8+ T cells were challenged intradermally in the ear with 2x106 dsRed L.
major. F) DTH response was monitored over the course of 3 days. G)
Parasite burden was determined at 72 hrs. Data shown are from one
experiment representative of two (n = 3 mice per group). H) Naïve and immune
flank skin were grafted side-by-side onto naïve recipients, then each graft was
challenged intradermally with 2x106 dsRed L. major. I) Parasite burden was
determined at 72 hrs. Data shown are from one experiment representative of
four (n = 5 mice per group). P < 0.05 = *; P < 0.01 = **; P < 0.001 = ***.

To determine if the DTH in leishmaniasis was dependent on either CD4+ or CD8+ T
cells, we individually depleted each subset in immune mice before challenge with L.
major, and then monitored the DTH response and parasite burden over 72 hrs (Fig. 1E).
αCD4 treatment, which depletes both circulating and tissue-resident CD4+ cells in our
hands (Fig. S1), completely ablated the DTH response (Fig. 1F), while effective CD8
depletion (Fig. S1) did not, suggesting that CD4+ cells are the critical drivers of this early
inflammation. Importantly, CD4+ cells, but not CD8+ T cells, were also required for the
decrease in parasites at 72 hrs (Fig. 1G).
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We next wanted to test if TRM cells were mediating the early control of the parasites. To
do so, we grafted naïve and immune skin side-by-side onto the flanks of naïve recipient
mice, challenged each graft, and measured the parasite burden three days later (Fig.
1H). As the graft recipients contain only naïve T cells, this approach enabled us to
specifically assess the protection mediated by TRM cells, which we have previously
shown to remain in the grafted tissue (Glennie et al., 2015). In all cases, the immune
grafts had significantly fewer parasites than their naïve counterparts at 72 hrs (Fig. 1I).
Taken together, these results indicate that CD4+ TRM cells mediate parasite protection in
immune skin at 72 hrs in a process that is independent of circulating CD4+ and CD8+ T
cells.

Rapid protection in immune mice is associated with recruitment of inflammatory
monocytes
To gain further insight into how this rapid protection is mediated, we analyzed the cells
recruited to the skin of naïve and immune mice 72 hrs after challenge. We compared
the numbers of CD90.2+ T cells, Ly6G+ neutrophils, Ly6C+ inflammatory monocytes,
MerTK+ CD64+ macrophages, and CD11c+ MHCII+ dendritic cells in naïve and immune
skin 72 hrs after infection (Fig 2A). As expected, we observed increased T cell
recruitment to immune skin consistent with previous results (Glennie et al., 2015; Peters
et al., 2014). However, a majority of the recruited cells were myeloid lineage cells,
specifically inflammatory monocytes (Fig. 2B, 2C). We analyzed the activation status of
these monocytes and found that they expressed high levels of MHCII, ROS, and iNOS.
Further, both MHCII and iNOS expression were significantly increased in the monocytes
recruited to immune skin compared with those recruited to naïve skin (Fig. 2D). Finally,
using fluorescent parasites, we found that greater than 70% of the infected cells in the
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skin of immune mice were inflammatory monocytes (Fig. 2E). Notably, these infected
cells contained fewer parasites per cell when compared with monocytes in naïve skin, as
demonstrated by the lower MFI of dsRed (Fig. 2F, 2G), and when counted in cytospins
(Fig. 2H). These data show that monocytes are highly recruited to immune skin where
they are more likely to be infected than other cell types, have a more activated
phenotype, and contain fewer parasites per infected cell. These results suggest that
inflammatory monocytes recruited by TRM cells might be better able to kill parasites, and
therefore we next investigated whether they were required for parasite control and if so
how they mediated protection.
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cytospin slide. Data shown are combined from two experiments (n = 5-6 mice
per group). P < 0.05 = *; P < 0.01 = **; P < 0.001 = ***.

Early protection is dependent on inflammatory monocytes
To assess the role of inflammatory monocytes in the early protection of immune mice,
we used a pair of depleting antibodies that target either Ly6G+ and Ly6C+ cells (and
thus deplete both neutrophils and monocytes) or Ly6G+ cells alone (and thus deplete
only neutrophils) (Fig. 3A, Fig. S2). Depletion of neutrophils alone had no effect on the
DTH response in immune mice, but depletion of both neutrophils and monocytes
dramatically reduced the early inflammatory response (Fig. 3B). Importantly, the
protection observed in immune mice was also completely ablated by the depletion of
monocytes and neutrophils, while depleting neutrophils alone did not have a significant
effect (Fig. 3C). Because activated CD4+ cells can also express Ly6C, we confirmed
that RB6-8C5 treatment did not reduce the frequency of Ly6C+ CD4+ T cells in the
spleen or ear after challenge (Fig. S3), or the frequency of leishmania-specific IFNγ+
skin-resident T cells (Fig. S4), which are intermediate for Ly6C expression (Fig. S5).
Taken together, these data suggest that inflammatory monocytes are the critical
mediators of early protection.
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from two experiments (n = 4 mice per group). J) Naïve and immune flank skin
were grafted side-by-side onto WT, PHOX-/-, or iNOS-/- naïve recipients, then
each graft was challenged with 2x106 dsRed L. major. K) Parasite burden was
determined in each graft by limiting dilution at 72 hrs. Data shown are from one
experiment representative of two (n = 5 mice per group). P < 0.05 = *; P < 0.01
= **; P < 0.001 = ***.
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To specifically address whether inflammatory monocyte recruitment is critical to early
protection against L. major, we assessed the response to challenge in CCR2-/- mice,
which contain monocytes that lack the ability to respond to CCL2 and CCL7 chemokine
signaling and therefore cannot be efficiently recruited to sites of inflammation (Tsou et
al., 2007; Boring et al., 1997). To do so, we grafted naïve and immune skin from WT
mice onto the flanks of naïve WT or CCR2-/- recipients, challenged with L. major, and
measured the parasite burden 72 hrs later (Fig. 3D). As previously observed, immune
skin had significantly fewer parasites compared to naïve skin in WT recipient mice (Fig.
3E). In contrast, the reduction of parasites in immune skin was lost in CCR2-/- recipient
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mice (Fig. 3E), and correlated with a loss of activated monocytes in the skin (Fig. 3F).
Together, these results demonstrate that it is recruited CCR2+ monocytes, rather than
resident myeloid cells, that are required for protection.

To further confirm that inflammatory monocytes were necessary for early protection, and
that this protection could be conferred in the absence of circulating T cells, we grafted
WT naïve and immune skin onto the flanks of RAG-/- recipient mice that lack T and B
lymphocytes. Additionally, we treated some of the mice with αGR1 clone RB6-8C5 to
deplete inflammatory monocytes and neutrophils as described above. We challenged
each graft with L. major and measured the parasite burden 72 hrs later (Fig. 3G). As
expected, immune grafts on RAG-/- mice contained significantly fewer parasites,
demonstrating that the protection observed at 72 hrs was independent of circulating
lymphocytes (Fig. 3H). Protection in immune skin was lost in mice treated with RB6-8C5
(Fig. 3H). When we quantified the number of Ly6C+ MHCII+ cells in each graft, we
found a strong correlation with the level of protection (Fig. 3I). Taken together, these
data further implicate inflammatory monocytes as the critical cell type required for early
protection.

To gain further insight into the mechanism by which the inflammatory monocytes might
control the parasites, we performed skin graft experiments in which we grafted naïve and
immune skin onto the flank of 1) WT naïve mice, 2) Phox-/- mice in which monocytes
lack the ability to produce ROS, or 3) iNOS-/- mice that have deficient NO production
(Fig. 3J). Grafts were then challenged with L. major, and the parasite burden measured
at 72 hrs. We found that the protection associated with immune skin was lost in both the
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Phox-/- and iNOS-/- mice (Fig. 3K), suggesting that both ROS and NO from
inflammatory monocytes are required for this early protection.

Early protection is not enhanced by circulating memory T cells
Although TRM cell-mediated recruitment of inflammatory monocytes was sufficient to
reduce the parasite burden at 72 hrs, we predicted that the presence of circulating
leishmania-specific T cells might further enhance immunity, as they are also recruited
early after challenge (Glennie et al., 2015, Peters et al. 2014). To examine the
contribution of circulating T cells, we pretreated immune mice with either FTY-720, which
prevents egress of T cells from tissues, or αCXCR3, which we previously demonstrated
blocks the ability of TRM cells to recruit effector T cells from circulation (Glennie et al.,
2015) (Fig. 4A). Despite the expected decrease in the number T cells recruited to the
challenge site (Fig. S6), neither treatment affected the DTH response (Fig. 4B), the
decrease in parasite burden (Fig. 4C), or the recruitment of monocytes (Fig. 4D).
Unexpectedly, this result demonstrates that DTH and early parasite control are not
enhanced by T cells from circulation, and implies that CD4+ TRM cells are solely
responsible for mediating these responses.
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Figure 4. Early protection is not enhanced by circulating memory T cells.
A) Naïve, immune, and immune mice treated with FTY-720 or αCXCR3 were
challenged intradermally in the ear with 2x106 dsRed L. major. B) DTH
response was monitored over the course of 3 days. C, D) Parasite burden (C)
and the number of Ly6C+ monocytes in the infection site (D) was determined at
72 hrs. Data shown are from one experiment representative of two (n = 3 mice
per group). E) Naïve, immune, naïve parabiotic, and immune parabiotic mice
were challenged intradermally in the ear with 2x106 dsRed L. major. F) DTH
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Figure S6. Efficacy of FTY-720 and αCXCR3 Blockade. Frequency or
number of CD4+ and CD8+ cells in the blood and challenged ear 72 hours after
infection of FTY-720 or αCXCR3 treated immune mice are shown.

To test if circulating T cells would provide protection in the absence of TRM cells, we
utilized a parabiotic model in which the circulations of naïve and immune mice were
surgically joined, allowing circulating T cells to equilibrate between the two animals,
while TRM cells remained exclusively in the immune partner (Fig. 4E). Each parabiont
was then challenged with L. major in the ear, and DTH and parasite number were
measured 72 hrs later. As expected, immune parabionts had the same DTH response,
monocyte recruitment, and parasite numbers as control immune mice (Fig. 4F-H). In
contrast, naïve parabionts, despite having a full complement of circulating memory T
cells, did not exhibit a DTH response, had defective monocyte recruitment, and lost the
early protection observed in immune mice (Fig. 4F-H). These results show that
circulating leishmania-specific T cells by themselves are unable to provide any
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protection at this early time point, further demonstrating that TRM cells are the critical
subset for this rapid protection.

Circulating memory T cells are not required to control low dose L. major infection
In contrast to the parasite control observed at 72 hrs in immune mice, we previously
found that when protection was assessed two weeks after challenge with 2 x 106
parasites, optimal parasite control depended upon both CD4+ TRM cells and circulating
effector T cells (Glennie et al. 2015). These results, in combination with our current
findings, suggest that while TRM cells may initially reduce the parasite number, the longterm consequences are limited in the absence of additional circulating T cells. However,
since parasite dose can significantly influence what is required for protection, and the
number of infective parasites transmitted by the sand fly is thought to be much lower
than 2 x 106 parasites (Kimblin et al., 2008), we next tested whether TRM cells might
provide protection greater than 72 hrs after challenge if fewer parasites were present in
the challenge inoculum.

First, we challenged naïve and immune mice with 103 parasites in the ear, measured the
DTH, and assessed the composition of cells recruited to the challenge site at 72 hrs.
Similar to our results with high dose challenge, immune mice had an increased DTH
response (Fig. 5A), there was a large population of inflammatory monocytes infiltrating
the lesions (Fig. 5B), and the monocytes had a more activated phenotype (Fig. 5C),
though the magnitude of the overall response was lower.
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Figure 5. Circulating memory T cells are not required to control low dose
L. major infection. A) Naïve and immune mice were challenged in the ear with
103 parasites and DTH was monitored over 72 hrs. B) Proportions of total
CD45+ population in naïve and immune ears 72 hrs after low dose challenge.
C) Representative histogram showing frequency of MHCII cells in naïve (black
line) and immune (gray line) mice 72 hrs after low dose challenge. Data shown
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flank skin were grafted side-by-side onto naïve WT or RAG-/- mice, then each
graft was challenged with 103 dsRed L. major. E) Parasite burden at 4 weeks
was compared between intact naïve and immune mice as well as naïve and
immune grafts on WT recipients. Data shown are from one experiment
representative of two (n = 5 or 9 mice per group). F) Parasite burden at 4
weeks was compared between naïve and immune grafts on WT or RAG-/recipients. Data shown are combined from two experiments (n = 5 mice per
group). P < 0.05 = *; P < 0.01 = **; P < 0.001 = ***.

To test if TRM cells could provide protection more than 72 hrs after challenge without
circulating T cells, we challenged intact naïve mice, immune mice, naïve grafts, and
immune grafts with 103 L. major, and measured parasite burdens 4 weeks later (Fig.
5D). As expected, intact immune mice were better protected than naïve mice against
low dose L. major challenge (Fig. 5E). However, immune skin grafts also showed
significantly better protection than their naïve counterparts, despite the absence of
circulating leishmania-specific effector T cells (Fig. 5E). These results demonstrate that
TRM cells do not require previously activated circulating T cells to provide protection as
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long as 4 weeks after low dose challenge. However, naïve leishmania-specific T cells
would be expanded during the 4 weeks of infection, and could contribute to the
protection we measured. Therefore, to test if TRM cells could provide protection without
any circulating lymphocytes, we grafted naïve and immune skin onto WT and RAG-/recipient mice, challenged with 103 parasites, and measured the parasite burden 4
weeks later (Fig. 5D). Surprisingly, we found that the immune grafts showed
significantly better control of the parasites in both WT and RAG-/- mice (Fig. 5F). While
circulating effector T cells may have potential to contribute to long-term immunity, these
results indicate that TRM cells and innate cells alone are sufficient to provide a significant
level of protection.

3.5 Discussion
We recently reported that TRM cells provide optimal immunity against L. major infection
by recruiting circulating leishmania-specific effector T cells to the site of infection
(Glennie et al., 2015). We now identify an additional, novel function for leishmaniaspecific TRM cells: to rapidly recruit and activate inflammatory monocytes at the site of
infection, resulting in a significant reduction in the initial parasite burden. Further, we
show that when the challenge inoculum is at a physiologically relevant dose, CD4+ TRM
and inflammatory monocytes exhibit significant control of the parasites, even when
circulating leishmania-specific effector T cells are not present. Together, these results
demonstrate that in addition to facilitating the recruitment of circulating effector T cells,
CD4+ TRM cells play a primary role in controlling parasites immediately after challenge,
which not only indicates the importance of generating CD4+ TRM cells in a vaccine, but
also expands our understanding of the functions of CD4+ TRM cells.
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Our experiments have identified CD4+ TRM cells as the critical cell subset required for
both the DTH response and the immediate control of leishmania infection. The response
is antigen specific as it is not induced by PBS injection, and is likely initiated via local
antigen presentation (Khan et al., 2016). The identification of TRM cells as required for
DTH responses was unexpected, since the prevailing view was that circulating effector T
cells mediated DTH. However, our results are similar to those that have been described
in studies of contact-hypersensitivity, where TRM cells mediated the inflammatory
response independent of circulating T cells (Gaide et al., 2015). Since DTH responses
can be elicited at sites distal to the initial site of infection, these results confirm that
CD4+ TRM are distributed and can function throughout the skin. Thus, our results extend
those of others which have focused on the functions of CD4+ TRM cells at the site of
infection (Iijima and Iwasaki, 2014; Collins et al., 2016). Surprisingly, neither CD8+ T
cells nor circulating effector T cells are required for the DTH response and the early
control of the parasites, implicating CD4+ TRM as the mediators of the initial inflammatory
responses.

We found that inflammatory monocytes are rapidly recruited to the lesion site by T RM
cells, and are responsible for the observed protection. Inflammatory monocytes are
important mediators of protection against many viral (Lim et al., 2011; Aldridge et al.,
2009) bacterial (Serbina et al., 2003; Peters et al., 2001; Moyat et al., 2015), fungal
(Hohl et al., 2009; John J. Osterholzer, Gwo-Hsiao Chen, Michal A. Olsewski, Jeffrey L.
Curtis, Gary B. Huffnagle, 2014), and parasitic infections (Robben et al., 2005; StraussAyali et al., 2007; León et al., 2007), and thus this mechanism of protection has the
potential to influence a number of different immune responses. Inflammatory monocytes
are known to be activated by memory T cells (Soudja et al., 2014), and restrict
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leishmania infection in certain contexts (León et al., 2007; Strauss-Ayali et al., 2007;
Goncalves et al., 2011), but their role in secondary leishmania infection and interaction
with TRM cells has not previously been appreciated. On the other hand, neutrophils did
not appear to be required for early protection or the recruitment of inflammatory
monocytes. This is in contrast to a primary infection where neutrophils may contribute to
the recruitment of dendritic cells (Charmoy et al., 2010). This difference is most likely
due to the presence of TRM cells, which are sufficient to mediate phagocyte recruitment
in secondary challenge. Indeed, CCL2 and CCL7 transcripts are both increased 12 hrs
after challenge in immune mice (Glennie et al., 2015), and CCR2 signaling is required
for the recruitment of inflammatory monocytes and subsequent protection.

ROS and NO from myeloid lineage cells have both been shown to have roles in
controlling leishmania infections, though results vary based on the site of infection, the
species of parasite involved, and whether the studies are done in mice or humans (Blos
et al., 2003; Stenger et al., 1996; Goncalves et al., 2011; Liew et al., 1991; Carneiro et
al., 2016; Novais et al., 2014). Nonetheless, it is clear in our model that both ROS and
NO are required for full protection early after challenge of immune mice, and neither is
sufficient alone. Thus, while most studies in mice have emphasized the central role of
NO, it has become clear that ROS can contribute to protection not only in humans but
also in the mouse. For example, following L. major infection Phox-/- mice can develop
chronic lesions long after presumed cure (Blos et al., 2003). Understanding why ROS is
required under certain conditions for control of leishmanial infections in mice is still not
well understood, although we would speculate that at the early time point the levels of
NO induced may be insufficient for parasite control, and ROS are required to boost the
killing by the inflammatory monocytes.
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Currently there is no human vaccine for leishmaniasis, which has been partially
attributed to the inability to maintain sufficient circulating effector T cells following
immunization (Mendez et al., 2004; Uzonna et al., 2001; Belkaid et al., 2002a). Thus, it
is the presence of low numbers of parasites in immune mice that are believed to
maintain maximal levels of responsive effector cells (Peters et al., 2014; Zaph et al.,
2004; Belkaid et al., 2002a; Mendez et al., 2004). However, our studies indicate that
TRM cells can mediate protection alone, suggesting that these T cells should be targeted
for a vaccine. Importantly, we found that they can survive in the absence of persistent
parasites (Glennie et al., 2015), similar to central memory T cells (Zaph et al., 2004), and
thus if generated in a vaccine may be maintained long-term. Thus, defining the
requirements for the generation and maintenance of TRM cells, as well as developing
vaccination strategies that induce TRM, are the next important steps in developing a
vaccine for leishmaniasis.

As our understanding of tissue resident T cells grows, more functions have been
attributed to TRM cells. CD8+ TRM can be directly cytotoxic (Kim et al., 1999; Masopust et
al., 2006), and IFNγ from TRM cells has been shown to drive recruitment of circulating T
cells (Schenkel et al., 2013; Glennie et al., 2015). Transcriptional analyses have
identified a core set of changes induced by TRM activation that induce a tissue state of
pathogen alert, capable of protecting against viral challenge non-specifically (Ariotti et
al., 2014; Schenkel et al., 2014a). However, this is the first demonstration to our
knowledge of TRM cells orchestrating the innate response and classic DTH responses by
recruiting inflammatory monocytes to the site of infection. This protective mechanism
has the potential to be relevant for a number of different intracellular infections, as DTH
responses are the hallmark of immunity against many infections and inflammatory
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monocytes are potent killers of many pathogens (Shi and Pamer, 2011). Although
circulating effector T cells are undoubtedly beneficial, in certain contexts the rapid
response provided by a combination of CD4+ TRM cells and inflammatory monocytes that
lessen the initial pathogen burden may be critical in limiting the magnitude of the
disease.

CHAPTER 4: Skin Resident CD4+ T Cells are Formed from Activated Effector Cells
that enter Uninflamed Skin Within 2 Weeks of Infection
4.1 Abstract
A population of CD4+ tissue-resident memory T cells forms after cutaneous leishmania
infection and appears to infiltrate throughout the skin, providing increased protection
against challenge. In order to leverage these cells for therapeutic advantage,
specifically in the context of a vaccine, we would like to understand how this population
of cells forms, and particularly how these cells gain entry to uninflamed skin sites. Here
we have examined the timing with which CD4+ TRM cells are established, finding that
they infiltrate uninflamed skin within 2 weeks of challenge, but can no longer enter once
infection is resolved. However, reactivation of memory T cells appears to license them
to enter uninflamed skin, and even boosts responses in immune mice. In a direct
comparison, we identify T effector cells as superior to T memory cells at entering
uninflamed skin, suggesting that these are the cells to target in a vaccine to generate
TRM cells.

4.2 Introduction
66

Tissue-resident T cells (TRM) have proven to be critical mediators of protection against a
number of different viral (Jiang et al., 2012; Mackay et al., 2012; Gebhardt et al., 2009;
Laidlaw et al., 2014; Teijaro et al., 2011; Schenkel et al., 2013; Shin and Iwasaki, 2012),
bacterial (Bergsbaken and Bevan, 2015; Sakai et al., 2014), and parasitic infections (Tse
et al., 2013; Glennie et al., 2015). Once a tissue specific infection is resolved, TRM cells
are retained at the site of infection, and are thus capable of initiating a secondary
response much more rapidly. While TRM cell-derived protective responses are well
studied at the site of infection, much less is known about TRM cells at secondary sites
distal to the initial site of challenge, though it is clear that TRM cells infiltrate tissue
broadly in at least some contexts (Masopust et al., 2001; Jiang et al., 2012; Glennie et
al., 2015).

Leishmania major is an intracellular, protozoan pathogen that causes self-limiting skin
lesions in humans and C57BL/6 mice. Similar to humans, immune mice that have
resolved a primary infection are highly resistant to reinfection, and we have shown that
this protection is at least partially dependent on a population of CD4+ TRM cells that
appear to distribute throughout the skin (Glennie et al., 2015, Glennie et al. 2017).
Importantly, although chronic parasites are maintained at the primary site of challenge,
parasites are not detected in distal skin sites, suggesting that TRM generation and
maintenance occurs independently of local inflammation.

Despite significant advances, the signals that drive the generation of TRM cells in tissue
remain somewhat undefined. Once T cells have entered the tissue, it is clear that
tissue-specific signals can drive the subsequent retention and maturation to the TRM
phenotype (Mackay et al., 2013; Adachi et al., 2015). Analysis of TCR usage by
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circulating and TRM cells has revealed that T cells in the tissue appear to come from a
subset of cells in circulation, though they are enriched for certain clones (Gaide et al.,
2015). A majority of TRM cell studies have focused on cells left at sites of inflammation
once infection is resolved. While the pathways guiding migration of lymphocytes into
sites of inflammation have been well established (Muller, 2013), the mechanisms by
which cells enter uninflamed tissue sites have been poorly studied. Nonetheless,
antigen-specific CD8+ T cells generated after viral infection have been shown to
establish residency in unchallenged sites (Masopust et al., 2001; Jiang et al., 2012), and
more recently there is evidence that CD4+ cells in the uninflamed skin can take on a
tissue-resident phenotype (Bromley et al., 2012; Collins et al., 2016).

Here, we examine the requirements for entry of leishmania-specific CD4+ T cells into
uninflamed skin sites after L. major challenge. We find that TRM cells are present in
uninflamed skin within 2 weeks of challenge, but are no longer generated once the
infection is resolved. Upon rechallenge, leishmania memory cells regain the ability to
form TRM cells, suggesting that activated effector cells are crucial for this process.
Indeed, when we compare effector and memory T cells directly, effector T cells are
superior at skin entry, with this process appearing to be dependent on proliferation, and
correlating with P and E selectin ligand expression. Fully defining the requirements for T
cell entry into skin will allow the specific targeting of these cells in a vaccine.

4.3 Materials and Methods
Ethics Statement
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This study was carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use Committee, University
of Pennsylvania Animal Welfare Assurance Number 805186.

Mice
C57BL/6 mice were purchased from the National Cancer Institute (Fredericksburg, MD).
Thy1.1/IFNγ reporter mice were obtained from Casey Weaver (University of Alabama
Birmingham, Birmingham Alabama (Harrington et al., 2008)). All mice were maintained
in a specific pathogen-free environment at the University of Pennsylvania Animal Care
Facility.

Parasites
L. major (Friedlin) parasites were grown in complete Schneider's insect medium
(GIBCO) supplemented with 20% heat-inactivated FBS, 2mM glutamine, 100 U/ml
penicillin, 100 µg/ml streptomycin, and 50 µg/mL G418 sulfate (Cellgro) (CSM).
Metacyclic enriched promastigotes were used for infection (Späth and Beverley, 2001).
Mice were infected with 2 x 106 L. major or 103 L. major intradermally in the ear.

Antibodies
For flow cytometry analysis αCD45 APC-eF780, αCD45.2 FITC, αCD45.1PE-Cy7,
αCD90.2 BV605, αCD11b BV650, αCD4 PE TexasRed, αCD8b PerCp/Cy5.5, αLy6C
AF700, αLy6G PacBlue, αIFNγ PE-Cy7, P and E selectin APC, or αThy1.1 PE-Cy7 were
incubated with single cell suspensions 30 minutes at 4°C and read on LSR Fortessa.
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Skin Preparation
For ear preparation, dorsal and ventral cutaneous layers of the ear were separated and
incubated in RPMI (Gibco) with 250 µg/mL Liberase TL (Roche) for 90 minutes at 37°C
in 5% CO2. Skin cells were then dissociated using a 40 µm cell strainer (BD
Pharmingen) and resuspended in complete RPMI media (cRPMI) containing 10% FBS,
100 U/ml penicillin, 100 µg/ml streptomycin, and 55 µM 2-Mercaptoethanol. For flank
skin preparation, a section of skin was harvested from the flank following hair removal
with an electric trimmer equipped with a two-hole precision blade (Wahl). Skin sections
were then minced with a sterile scalpel blade into ~2mm sections, and incubated in
RPMI containing 1 mg each of type III and type IV collagenase (Worthington) for 120
minutes with vortexing every 30 minutes. The resulting solution was passed through a
40 µm cell strainer and resuspended in cRPMI. BMDCs for restimulations were
generated by culturing C57BL/6 bone marrow in GM-CSF supplemented cRPMI for 7-11
days. BMDCs were then harvested and infected 5-8 hours with stationary phase L.
major at a ratio of 10:1 in the presence of 1 µg/ml CpG and LPS. Infected BMDCs were
incubated at a ratio of 1:5 with 106 skin cells in 24 well plates for 12-16 hours. Cells were
incubated for the last 4 hours with 5 µg/ml BFA (eBioscience), stained for IFNγ, and
analyzed by flow cytometry.

Skin grafts
Skin grafts were performed as previously described (Glennie et al., 2015). Briefly, donor
skin was prepared under sterile conditions from naïve and immune mouse flank skin by
shaving, depilating, cleaning with chlorhexidine (Vetoquinol), then excising the skin using
sterile 8mm biopsy punches (Miltex). Grafts were placed onto a fresh graft bed prepared
by excising skin using a 6mm biopsy punch. All mice were anesthetized, received
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analgesics, and were monitored post-operatively as previously described. In challenge
experiments, graft skin was injected intradermally with 2 x 106 metacyclic L. major 14-20
days after grafting.

Parabiosis
Congenically disparate mice were cohoused 2 weeks prior to surgery. After induction of
anesthesia with isoflorane, each received 0.1mg/kg buprenorphine subcutaneously (s.q.)
as preemptive analgesia. The surgical site was shaved and aseptically prepared with
chlorhexidine scrub. A longitudinal skin incision was made on the mirroring side in each
mouse starting at 0.5 cm above the elbow and ending 0.5 cm below the knee joint. The
left elbow and knee of one animal were attached to the right elbow and knee of the other
with a 3-0 ethilon suture (Ethicon) around each joint beneath the skin in a manner loose
enough to not disrupt circulation to the distal limb. The dorsal and ventral skin edges
created by the flank incision from one mouse were sutured to the respective skin edges
of the second mouse using a continuous absorbable 5-0 vicryl suture patter (Ethicon).
Suture glue (Abbott laboratories) was used to approximate skin edges. 0.5 ml of 0.9%
NaCl was administered s.q. to each mouse to prevent dehydration in the immediate
post-operative recovery period, and mice were monitored twice daily for the first 48 hrs
post-operatively, then observed daily for signs of surgical site complications, pain, or
discomfort. In challenge experiments, ears were infected intradermally with 2 x 106
metacyclic L. major 14-20 days after surgery.

Adoptive transfer
Single cell suspensions from spleen and lymph node were incubated 4 minutes at room
temperature in the presence of 2.5 µM CFSE or CTV in the dark. The reaction was
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quenched with 10% FBS and resuspended at 5-10 x 107 cells/mL in PBS, then
transferred i.v. in 400 µL volume into recipient mice.

LCMV infection
C57BL/6 mice were injected i.p. with 2 x 105 pfu LCMV Armstrong. LCMV immune
donor mice were sacrificed 5 or 40 days after infection, single cell suspensions were
generated from spleen and lymph node, CFSE or CTV labeled, and transferred i.v. into
recipient mice.

Statistical analysis
Statistical analysis was performed with the Mann-Whitney test (two-sided t-test, paired
or unpaired where applicable), ANOVA, or 2-way ANOVA in Prism software (GraphPad).

4.4 Results

L. major-specific CD4+ T cells take up residency in uninflamed skin within 2 weeks
of challenge

Mice that resolve a primary L. major infection develop an antigen-specific memory T cell
response throughout the skin that appears to persist for the life of the animal (Glennie et
al., 2015). To assess how early this population of TRM cells forms after infection, we
challenged WT C57BL/6 mice in the ear, waited 1 or 2 weeks after infection, then
restimulated skin homogenates from the uninfected flank skin with L. major infected
BMDCs (Fig. 1A). One week after infection, we were unable to detect a leishmania
specific response above background (Fig. 1B), suggesting that TRM cells had yet to form
at this time. In contrast, there was a significant increase in leishmania-specific cells in
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the flank skin 2 weeks post infection (Fig. 1B), indicating that leishmania-specific cells
can enter uninflamed skin within the first 2 weeks of challenge.
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Figure 1. L. major-specific CD4+ T cells take up residency in uninflamed
skin within 2 weeks of challenge. A) C57BL/6 mice were challenged
intradermally in the ear with 2 x 106 L. major. 1 or 2 weeks after challenge, flank
skin was harvested, restimulated with L. major infected BMDCs, and leishmaniaspecific cells were assessed by IFNγ production. B) The frequency of IFNγ
producing CD4+ T cells in flank skin 1 or 2 weeks after challenge as
represented by Thy1.1 surface expression in IFNγ/Thy1.1 knock-in reporter
mice (Harrington et al. 2008). C) Skin from mice that had been infected for 2
weeks was grafted onto naïve recipients. 2 weeks later, cells from the graft skin
were restimulated with L. major antigen, and antigen specific responses were
measured by IFNγ production. D) The number of leishmania-specific T cells
contained in skin grafts at the time of grafting (day 0), and 2 weeks after skin
grafting.

To test if these leishmania-specific cells in flank skin 2 weeks after infection were
forming a tissue-resident population, we performed skin grafts in which skin from the
flanks of mice that had been infected 2 weeks earlier were grafted onto naïve recipients.
After allowing 2 weeks for the grafts to heal and immune cells to equilibrate, we
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harvested the grafts, restimulated with L. major antigens, and assessed leishmaniaspecific CD4+ T cell responses by IFNγ production (Fig. 1C). Strikingly, we observed
the same number of cells in the skin grafts 2 weeks after transplant, suggesting that
these cells did not recirculate. Together, these data demonstrate that leishmaniaspecific CD4+ T cells enter uninflamed skin sites within 2 weeks of challenge, and even
at this early time point they are capable of establishing tissue-residency.

L. major-specific T cells no longer enter uninflamed skin once the infection is
resolved

Having established that TRM cells can enter uninflamed skin very early after infection, we
next wanted to assess their ability to continually enter uninflamed skin once the infection
is resolved. To do so, we used parabiosis in which we surgically linked the circulations
of naïve and immune mice that had resolved a primary infection. As expected, we
observed equal sharing of lymphocyte populations in the blood 2 weeks after joining, as
represented by the frequencies of naïve (CD45.2) and immune (CD45.1) origin cells
recovered from blood of the naïve animals (Fig. 2A). Importantly, when we restimulated
cells from the blood with L. major infected BMDCs, we also saw equal mixing of IFNγ+,
leishmania-specific CD4+ T cells (Fig. 2B). Strikingly, although we saw some entry of
total CD4+ cells into the flank skin, IFNγ+ leishmania-specific cells could only be
recovered from the flanks of the immune mice, suggesting that memory cells are unable
to efficiently enter naïve skin, at least within the 2 weeks of shared circulation.
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Figure 2. L. major-specific effector T cells no longer enter non-inflamed
skin once infection is resolved. A) Proportions of CD4+ and CD8+ T cells of
naïve (white) or immune (black) origin found in naïve parabionts 2.5 weeks after
joining.
B) Representative and combined data showing frequency of
leishmania-specific, IFNγ+ cells in the blood and flank of naïve and immune
parabionts 2.5 weeks after surgery upon restimulation with L. major infected
BMDCs. C) Total splenocytes from CD45.1 immune mice were transferred into
naïve CD45.2 recipient mice. 2 weeks later, the distribution of transferred
CD4+ cells in spleen, DLN, ear, and flank were assessed by flow cytometry. D)
The number of transferred cells recovered from spleen, DLN, ear, and flank 2
weeks after transfer.

To confirm that memory T cells were unable to efficiently enter uninflamed skin sites, we
directly transferred labeled (CD45.1) splenocytes from immune mice, which are enriched
for leishmania-specific CD4+ T cells, into naïve (CD45.2) recipient mice. 2 weeks later,
we harvested various tissue sites to assess the migration of the transferred CD4+ cells
(Fig 2C). As expected, we found significant populations of transferred CD4+ cells in the
spleen and cervical draining lymph nodes of all recipient mice (Fig. 2D). In contrast, we
saw virtually no infiltration of the transferred cells into either the ear or the flank skin
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within 2 weeks (Fig. 2D), again suggesting that CD4+ cells from the memory phase of
infection are inefficient at trafficking into uninflamed skin.

Memory cells regain the ability to enter uninflamed skin following rechallenge

We next wanted to ask if leishmania memory cells would regain the ability to enter
uninflamed skin upon restimulation with antigen. To do so, we set up naïve and immune
parabiotic pairs to ensure we would have a physiologic level of circulating memory cells
with access to naïve skin. We then challenged each mouse intradermally in the ear with
L. major, and 72 hours later assessed the migration of leishmania-specific CD4+ T cells
into the flank skin compared with unchallenged parabionts (Fig. 3A). As previously
observed, in the absence of challenge we did not see any migration of cells into naïve
flank skin, while we did observe a population of TRM cells in the immune mice (Fig. 3B).
Strikingly, upon challenge we not only observed a population of cells that could infiltrate
the naïve skin, but also observed an increase in the number of responsive cells in the
immune flanks (Fig. 3B). These data suggest that rechallenge does indeed generate a
population of effector cells that infiltrate naïve skin and boost responses in immune skin.
Moreover, this change happens very rapidly, and can be observed within 72 hours of
restimulation.
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Figure 3. Memory cells regain the ability to enter uninflamed skin
following rechallenge. A) Naïve and immune mice were linked by parabiotic
surgery. 2 weeks later, each naïve and immune mouse was challenged in the
contralateral ear, and then leishmania-specific responses were assessed by in
vitro restimulation with L. major infected BMDCs. B) Frequency of leishmaniaspecific cells in the flank skin of naïve and immune parabionts with or without
rechallenge 72 hrs earlier. C) Total splenocytes from CD45.1 immune mice
were transferred into naïve CD45.2 recipient mice with or without L. major
challenge. 2 weeks later, the distribution of transferred CD4+ cells in the ear
and flank skin were assessed by flow cytometry. D) The number of transferred
cells recovered from ear and flank skin with and without L. major challenge 2
weeks after transfer.

To test this hypothesis another way, we adoptively transferred labeled (CD45.1) total
splenocytes from immune mice into naïve (CD45.2) recipients, challenged intradermally
in the ear with L. major, and 2 weeks later measured the infiltration of transferred cells
into the skin (Fig. 3C). As previously observed, in the absence of L. major challenge
leishmania memory cells did not significantly infiltrate ear or flank skin (Fig. 3D). As
expected, 2 weeks after challenge we were able to recover many cells from the
challenged ear, suggesting that these cells were capable of responding to inflammation
(Fig. 3D). Again, we also found a significant infiltration of our transferred cells into
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uninflamed flank skin, indicating that restimulation of leishmania memory cells is
sufficient for allowing them to regain the ability to enter uninflamed skin sites.

Recently activated effector cells are superior to memory cells at entering
uninflamed skin

These findings suggest that recently activated effector cells are superior to memory cells
at forming TRM cells because they are better able to enter uninflamed skin sites. To
confirm that the cells entering uninflamed sites were indeed recently activated, we used
CFSE labeling dye to assess T cell proliferation in response to antigen stimulation. As
before, we transferred congenically disparate, CFSE labeled cells into naïve mice,
challenged with L. major, and 2 weeks later examined CFSE dilution on cells in various
tissues (Fig. 4A). As expected, there was very low background proliferation of
transferred cells in the skin draining lymph node of mice that were not challenged (Fig.
4B). In contrast, cells from the draining lymph node of challenged mice showed robust,
presumably antigen-specific proliferation, causing roughly half the cells to dilute their
CFSE (Fig. 4B). Convincingly, virtually all the cells we were able to detect in the
uninflamed flank skin had completely diluted CFSE (Fig. 4B), indicating that they indeed
had been recently activated, and suggesting that this may be a requirement for entry into
uninflamed skin.

P and E selectin ligands (PESL) are expressed by activated T cells, and augment entry
into inflamed skin sites by binding to their receptors on the surface of activated
endothelial cells, subsequently leading to extravasation into the tissue (Tietz et al.,
1998). We therefore examined the expression of P and E selectin ligands on transferred
CD4+ cells that we recovered from various sites to determine if they were associated
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with activation or tissue entry. PESL expression was very low on CD4+ cells in
secondary lymphoid organs, consistent with a less activated phenotype (Fig. 4C). By
comparison, CD4+ cells that infiltrated the challenged ear had relatively higher
expression of PESL, though they were still only expressed on roughly 30% of cells (Fig.
4C). In contrast, greater than 90% of CD4+ cells that entered the uninflamed flank skin
stained positive for PESL (Fig. 4C), indicating that these cells have not only proliferated,
but they have also upregulated molecules associated with entry into skin.
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Figure 4. Recently activated effector cells are superior to memory cells at
entering uninflamed skin. A) CFSE labeled splenocytes from leishmania
immune mice were adoptively transferred into naïve recipients that were then
challenged with L. major. 2 weeks later, CFSE and PESL expression on
transferred cells were measured in various tissue sites. B) The frequency of
transferred cells that had diluted CFSE in challenged and unchallenged DLNs,
as well as the flank skin of mice 2 weeks post challenge. C) The frequency of
transferred CD4+ cells expressing PESL in spleen, DLN, ear, and flank 2 weeks
after L. major challenge. D) Total splenocytes from LCMV infected mice at the
effector phase (day 5) or memory phase (day 40) were labeled with CFSE or
CTV respectively, then adoptively transferred into 2 week post L. major infected
recipients. 36 hours later, the migration and PESL expression on transferred
cells was examined in the blood and flank skin. E) The frequency of LCMV
memory or effector phase cells recovered from the blood (left) or flank (right) 36
hours after transfer. F) The frequency of LCMV memory and effector phase
cells expressing PESL in the blood or flank skin 36 hours after transfer.
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To test if this phenomenon was specific to L. major infection, and take advantage of a
system in which the kinetics of infection are better defined, we next directly compared
the migration of LCMV specific effector and memory phase CD4+ T cells. To do so, we
isolated total splenocytes from LCMV infected mice at peak infection (5 dpi) when they
would have a large population of effector phenotype cells, and in the memory phase (40
dpi) when the virus is totally cleared and responding T cells have taken on a memory
phenotype (Fig. 4D). We then transferred these cells in equal numbers into mice that
were 2 weeks post L. major infection, and assessed their migration into tissue 36 hrs
later by flow cytometry (Fig. 4D). Importantly, we observed similar frequencies of our
transferred CD4+ cells in the blood (Fig. 4E, left), indicating that we transferred similar
numbers of cells. However, when we examined the number of cells of each phenotype
in the flank skin, we saw that only effector cells were capable of migrating in, while
virtually no memory cells could be detected (Fig. 4E, right). Additionally, when we
examined PESL expression, effector phase CD4+ cells had significantly higher
expression both in the blood and even more so in the flank skin (Fig. 4F). Taken
together, these data further indicate that recently activated effector cells are capable of
infiltrating uninflamed skin sites, while quiescent memory cells are not, and that the
ability to do so correlates with activation markers, such as PESL expression.

4.5 Discussion
Despite a number of examples of TRM cells providing rapid protection against secondary
infection, and a number of descriptions of the requirements for retention of CD8+ T cells
(Mackay et al., 2013) and even CD4+ T cells (Adachi et al., 2015; Iijima and Iwasaki,
2014) in tissue, relatively little is known about how TRM cells enter tissue, particularly at
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sites distal to infection. Here, we study leishmania-specific TRM cells to try and elucidate
some of the mechanisms by which these cells gain entry into the skin, specifically in
uninflamed sites. Strikingly, we find that entry occurs as early as 2 weeks after infection,
but seems to be dramatically restricted once infection is resolved. Further, we find that
proliferated effector cells are far superior to memory cells at entering uninflamed skin,
suggesting that these are the cells to target for inducing TRM cells.

It has been appreciated that CD4+ T cells are much more mobile in the skin than CD8+
T cells, correlating with their predilection for localizing to the dermis, while CD8+ T cells
are more likely to be in the epidermis (Gebhardt et al., 2011). Moreover, CD4+ T cells
are much more likely to be found migrating out of the skin at steady state (Debes et al.,
2006; Bromley et al., 2012). Together, these data suggest that CD4+ T cells are much
more migratory within tertiary tissues, and thus may be more inclined to enter
uninflamed skin than other lymphocytes. Indeed, it has been observed that if you wait
long enough after parabiosis, CD4+ cells in the skin will completely equilibrate in naïve
SPF mice, suggesting that they have a significant ability to migrate through tissue
(Collins et al., 2016). Nonetheless, a number of different CD4+ TRM cell populations
have been identified (Iijima and Iwasaki, 2014; Laidlaw et al., 2014; Collins et al., 2016;
Teijaro et al., 2011), and we have identified a population of non-circulating leishmaniaspecific TRM cells in the skin (Glennie et al., 2015, 2017). Together, these data suggest
that while CD4+ cells have an ability to migrate relatively well in tissue, particularly in
comparison to their CD8+ counterparts, infection induced changes in the T cells, the
environment, or some combination of the two licenses these CD4+ cells to enter tissue
and establish residency. Our findings that highly proliferated, activated effector cells are
the cells most likely to enter uninflamed tissue indicate that there may be T cell intrinsic
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changes that increase their ability to enter, which presumably leads to their increased
retention in the skin. Going forward, we will need to validate that those cells that enter
skin are in fact retained, though based on our skin graft results they appear to be
retained for at least 2 weeks after grafting.

Unlike other tissues, the skin is constantly in direct contact with the exterior environment.
Factors such as the skin microbiome and mechanical disruption caused by physical
contact have the potential to influence TRM cell generation. In fact, colonization of mouse
skin with a single bacteria species has been shown to increase the generation of some
TRM cell populations in specific contexts (Naik et al., 2015, 2012). In vaccinia infection,
skin-scarification appears to increase the generation of TRM cells (Liu et al., 2010; Jiang
et al., 2012), but the extent to which physical injury might promote the generation of TRM
cells at sites distal to the site of infection remains to be fully examined. Interestingly, the
topography of hair follicles and signals derived from hair follicle-associated microbiota
may be important for TRM cell maintenance (Adachi et al., 2015), but the contributions of
these factors in human skin remain to be defined.

Intriguingly, we found that rechallenge of parabiotic pairs containing one naïve and one
immune animal not only led to the generation of a leishmania-specific skin response in
the naïve animals, but also appeared to boost the existing TRM response in the immune
parabionts. This is exciting, because it suggests that boosting via vaccination, or even
through naturally occurring reinfection, may lead to an increase in TRM cells and thus an
increase in protective immunity. In future studies, it will be useful to determine the extent
to which repeated inoculation increases skin-resident as well as circulating immune
responses in order to optimize a potential vaccine strategy. From this study, one can
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conclude that multiple rounds of boosting and the generation of large pools of highly
proliferated, recently activated effector cells may be critical for a vaccine to generate TRM
cells. Further defining the exact transcription factors and surface molecules required for
skin entry will be required to fully understand how these cells are formed, and to allow
them to be leveraged in a vaccine.

CHAPTER 5: DISCUSSION
5.1 Developing a cutaneous leishmaniasis vaccine
Cutaneous leishmaniasis poses a conundrum for vaccine development. On the one
hand, control of a primary infection is highly protective, a prospect that bodes well for
any potential vaccine. On the other hand, the parasite is never fully cleared, and forcing
elimination of the parasite reduces immunity to reinfection (Uzonna et al., 2001; Belkaid
et al., 2002a). While a live vaccine might provide the best protection, it may be difficult
to deliver such a vaccine due to ethical and logistical concerns. Encouragingly, it is not
required that a cutaneous leishmaniasis vaccine provides sterile immunity, as it is
apparent that low levels of parasites can be maintained without pathology. Therefore,
the goal of a cutaneous leishmaniasis vaccine might not be to completely eliminate the
parasites but instead reduce the parasite load below a certain threshold, and in
particular decrease the incidence of the most pathologic outcomes of disease such as
mucosal, disseminated, and diffuse cutaneous leishmaniasis.

Circulating CD4+ TEff cells are potent mediators of immunity and thus are attractive to
target in a vaccine. Unfortunately, these T cells appear to require parasites to persist,
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and therefore maintaining them will rely on a strategy that supplies continuous antigen
either through a live-attenuated pathogen, frequent boosts, or some other persistent
delivery platform. The development of a safe live-attenuated parasite that maintains TEff,
TCM, and TRM may be the simplest path to an effective vaccine, but has proven difficult to
develop (Kedzierski et al., 2006; Palatnik-de-Sousa, 2008). Another barrier to the
generation of a CD4+ T cell vaccine has been the lack of well-defined immunodominant
CD4+ T cell epitopes, as most immunization strategies have required complex
polyprotein constructs to induce responses (Costa et al., 2011; Duthie et al., 2016). The
recent identification of a protein, phosphoenolpyruvate carboxykinase, that reacts with
approximately 20% of L. major-specific CD4+ T cells and has broad cross-reactivity may
help resolve this need, and will also be an invaluable tool for assessing CD4+ responses
(Mou et al., 2015). Nevertheless, continuing efforts to discover conserved,
immunostimulatory antigens may be necessary to get the coverage required for robust
vaccine-induced immunity.

Fortunately, while TEff cells require persistent antigen, there are at least two populations
of memory T cells that are maintained in the absence of persistent parasites. TCM cells
persist and alone can provide some resistance in mice, though the protection is delayed
compared to TEff cells (Zaph et al., 2004). CCR7+ CD4+ memory cells that show
increased proliferative capacity in response to leishmania antigen have also been
identified in cutaneous leishmaniasis patients that have healed (Keshavarz Valian et al.,
2013), suggesting that TCM cells are generated in humans as well.

TRM cells have never been targeted in a leishmania vaccine, and may be the missing link
for optimal vaccine-induced protection. Indeed, when challenged by sand fly bite instead
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of needle injection, only immune mice and not vaccinated mice are protected against L.
major (Peters et al., 2009). Since immune mice contain a population of TRM cells, this
result may demonstrate the importance of TRM cells for a vaccine. Our finding that TRM
cells mediate the DTH response in mice (Glennie et al., 2017), and the fact that the DTH
response correlates with protection in mice and in humans, additionally suggests that
TRM cells may have a critical role to play (Rossell et al., 1987; Sassi et al., 1999; Schnorr
et al., 2012). Intriguingly, since all species of the parasite are transmitted through the
skin, TRM cells may be able to provide significant cross-protection, even against the
visceral form of the disease. The hallmark of TRM cell-mediated protection is a rapid
response, which may be critical for controlling the parasites before they have time to
replicate and expand extensively. Since TRM cells respond rapidly and TCM cells maintain
a reservoir of responsive cells, a vaccine that combines the induction of TRM cells and
circulating TCM responses may offer the most realistic hope of a safe, effective vaccine
for cutaneous leishmaniasis.

5.2 Mechanisms of TRM induced protection
There are several potential mechanisms by which Trm cells could provide protection
against a challenge infection. While one function of CD8+ TRM cells appears to be
production of effector molecules that can directly kill target cells (Kim et al., 1999;
Masopust et al., 2006; Steinbach et al., 2016), most of the identified TRM cell functions
are mediated indirectly through downstream effects of inflammatory cytokine production.
For example, recent studies of CD8+ TRM cells in the female reproductive tract
demonstrated IFNγ-dependent B and T cell recruitment (Schenkel et al., 2013), along
with local DC maturation, and NK cell activation (Schenkel, 2014). Several studies have
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demonstrated broad transcriptional changes occurring in tissue after TRM cell activation
that result in protection (Schenkel, 2014; Ariotti et al., 2014; Glennie et al., 2015), but
relatively few have delved into the details of how this protection is mediated.

We have identified two specific effector functions of TRM cells during cutaneous
leishmaniasis: 1) To promote CXCR3-dependent recruitment of circulating effector T
cells, and 2) To activate an enhanced innate inflammatory response and CCR2dependent recruitment of inflammatory monocytes. Our findings extend those from
CD8+ TRM cells in the FRT to CD4+ TRM cells in the skin, and this process probably
occurs by a similar mechanism, which may be at least in part mediated by activation of
the endothelium and upregulation of VCAM-1 (Schenkel, 2014). This result is interesting
because it demonstrates for the first time that a CD4+ TRM population can promote T cell
recruitment, and it suggests that even a small number of cells distributed broadly
throughout the tissue can mobilize a much larger adaptive immune response by calling
circulating T cells into the tissue to perpetuate the response.

More interestingly, we have also identified a novel mechanism by which TRM cells
function in recruiting inflammatory monocytes into the tissue, resulting in direct control of
a pathogen (Glennie et al., 2017). While other groups have suggested or demonstrated
interactions between TRM cells and innate cells (Iijima and Iwasaki, 2014; Schenkel,
2014; Adachi et al., 2015; Collins et al., 2016), none to our knowledge have shown TRM
cell-mediated protection through innate cell recruitment and activation. This discovery
may have a broad impact on a number of different infections in which inflammatory
monocytes promote protection (Lim et al., 2011; Aldridge et al., 2009; Serbina et al.,
2003; Peters et al., 2001; Moyat et al., 2015; Hohl et al., 2009; John J. Osterholzer,
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Gwo-Hsiao Chen, Michal A. Olsewski, Jeffrey L. Curtis, Gary B. Huffnagle, 2014;
Robben et al., 2005; Strauss-Ayali et al., 2007; León et al., 2007). Further, our finding
that TRM cell driven recruitment of inflammatory monocytes is responsible for the DTH
response extends findings from contact hypersensitivity models (Adachi et al., 2015;
Gaide et al., 2015), and suggests that this correlate of adaptive immunity is also
dependent on TRM cells and not circulating cells, which has implications for a number of
diseases. Several questions remain going forward, including what T cell function
initiates the signaling cascade that leads to inflammatory monocyte recruitment, the cell
types involved in inflammatory chemokine production, and the relative roles of ROS and
NO in protection. Further elucidation of additional cytokine dependent TRM cell functions,
as well as functions that might be mediated by direct cell-to-cell contact is warranted.

5.3 Inducing and maintaining TRM cells
If TRM cells in fact offer hope as a vaccine strategy, then it is critical that we understand
the requirements for the induction and maintenance of TRM cell populations.
Unfortunately, it is still poorly understood how to target TRM cells through vaccination,
although one important factor may be the route of inoculation. Skin-scarification has
been shown to induce increased proliferation of T cells in skin-draining lymph nodes, as
well as increased homing to peripheral tissue (Liu et al., 2010; Hersperger et al., 2014).
These studies suggest that a delivery strategy involving epidermal abrasion may
generate TRM cells more effectively than other delivery methods, though the exact
mechanisms by which this occurs still remain unclear.
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We have explored this concept in a preliminary study using two different methods of
DNA vaccination. Intramuscular DNA vaccination with subsequent electroporation has
been shown to generate increased uptake of DNA and expression of protein antigens,
subsequently leading to stronger CD4+, CD8+, and antibody responses against the
target antigen (Sardesai and Weiner, 2011). Intradermal DNA electroporation involves
the injection of DNA directly into the skin, followed by the delivery of an electronic pulse
which is designed to increase uptake of the DNA, but may also cause some level of
tissue damage. Our preliminary data suggest that antigen delivered via intradermal
vaccination generates significantly better cutaneous CD4+ responses both at the site of
vaccination, and at distant skin sites (Fig. 1). This result reaffirms that vaccination via
the tissue of interest may be important for TRM cell generation. As a natural infection
model that generates skin-associated TRM cell responses not just at the infection site but
also in uninflamed skin sites, leishmaniasis offers an opportunity to further understand
the requirements for generating TRM cells.

Figure 1. Intradermal DNA electroporation is superior to intramuscular at
eliciting skin-associated T cell responses. (Left) The number of vaccinespecific IFNγ-producing splenocytes was determined by Elispot 24 days after
vaccination of C57BL/6 mice either intramuscularly (IM) or intradermally (ID).
(Right) In the same mice, the number of vaccine-specific IFNγ-producing T cells
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in the skin at the site of vaccination, or at a distal, contralateral site were
quantified by flow cytometry 24 days after vaccination.

Continuing to explore mechanisms that promote the infiltration and maintenance of
antigen-specific cells into the tissue will be critical for promoting TRM cell populations.
Another method that has seen some success is the topical application of chemokines.
Specifically, the application of CXCL9 and CXCL10, which drive recruitment and
retention of CXCR3+ effector T cells, directly into the female reproductive tract promoted
the migration of HSV-2 specific T cells into the tissue, which subsequently provided
enhanced protection against challenge (Shin and Iwasaki, 2012). This "prime and pull"
method of vaccination, though perhaps impractical in humans, represents a proof of
principle that the artificial augmentation of inflammatory cues in the tissue may drive
increased TRM cell formation.

One critical question to understand is what type of T cells give rise to TRM cells,
specifically whether effector or memory phenotype T cells are better at forming TRM cell
populations. In chapter 4 we investigated this question in the leishmania infection
model, and discovered that recently activated, recently proliferated, and PESL+ cells
appeared to best be able to enter skin, and remain resident there for at least 2 weeks.
However, it has been proposed in other models that pre-TRM cells are in fact less highly
differentiated cells, allowing them to take on a memory phenotype once they lodge in
tissue (Sheridan et al., 2014). On the other hand, emerging evidence indicates that TRM
cells more closely mimic T effector cells, which may suggest that they form from effector
T cell precursors (Mackay et al., 2016, 2013; Gaide et al., 2015). Continuing to dissect
what type of T cells best form TRM cells will be important for generating them
experimentally.
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Moreover, the extent to which T cell intrinsic factors versus environmental factors drive
TRM cell formation remains to be defined. Some studies, including ours, have suggested
that there may be inherent differences between the T cells that do or do not enter tissue
(Gaide et al., 2015). However, there is ample evidence that once in the tissue, specific
tissue-derived signals augment or maintain TRM cell populations, and lead to specific
changes in TRM cell phenotype (Masopust et al., 2006; Mackay et al., 2013; Iijima and
Iwasaki, 2014; Adachi et al., 2015). Additionally, there may be infection-induced
changes in the epithelium, resulting in enhanced T cell infiltration regardless of T cell
phenotype (Iijima and Iwasaki, 2015; Ebel et al., 2015; Schenkel, 2014). Defining the
extent to which each process plays a role in TRM cell generation and maintenance is
important to our understanding of these cells.

Similarly, the role that antigen might play in the establishment and maintenance of T RM
cells in the tissue remains ill-defined. In leishmaniasis, where primary infection results in
the chronic persistence of parasites at the site of infection and in the draining lymph
node, antigen will always be present in an immune animal, though it does not persist in
sites where resident memory cells form (Nicolas et al., 2000). Based on our skin graft
results, antigen does not appear to be required for parasites to persist at least 4 weeks
after transfer (Glennie et al., 2015), though this does not rule out a role for antigen in the
formation of TRM cell populations. Indeed, a recent study nicely demonstrated that the
recognition of cognate antigen within tissue can substantially augment the formation and
establishment of residency within tissue (Khan et al., 2016). However, several other
studies have demonstrated that TRM cell formation does not rely on the presence of
antigen, and that TRM cells can be maintained in the absence of any persistent antigen
(Casey et al., 2012; Mackay et al., 2012). Undoubtedly, the requirement for antigen may
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vary based on the infection, infection site, and the tissues involved. Nevertheless, there
is certainly a role that antigen can play both in the initiation of TRM cell forming
responses, and in augmenting TRM cell responses in the tissue. However, since antigen
is not absolutely required for the maintenance of TRM cell populations, there is hope that
these cells can be retained even when antigen levels fade, as occurs during vaccination.

Many studies have sought to establish specific factors associated with TRM cells, with
varying degrees of success. Initially, it appeared that integrin-α component CD103
would be a definitive marker for tissue-resident cells (Kim et al., 1999; Schön et al.,
1999). Subsequent studies, however, revealed that not only was it less ubiquitously
expressed by CD4+ compared to CD8+ TRM cells (Teijaro et al., 2011; Shin and Iwasaki,
2012; Laidlaw et al., 2014), but also that CD103- CD8+ TRM cells could exist as well
(Anderson et al., 2012; Bergsbaken and Bevan, 2015). Upregulation of the CD69 axis
and associated reduction in surface receptor S1P1R, as well as transcription factor KLF2
have also appeared to be good candidates as TRM cell markers, and in many cases do
associate with TRM cell formation (Masopust et al., 2006; Skon et al., 2013), but follow-up
studies have demonstrated that these too are imperfect markers (Anderson et al., 2014;
Watanabe et al., 2015). Genome wide expression profiling has revealed that there are
some signatures that associate specifically with TRM cells across a variety of infections
and a variety of tissues (Mackay et al., 2013). Recently, transcription factors Blimp-1
and Hobit have been shown to specifically promote the retention of CD8+ TRM cells in
tissue (Mackay et al., 2016). Preliminary data from leishmania infected mice suggest
that these factors may also associate with CD4+ TRM cells, though follow up studies will
be needed to confirm these data (Fig. 2). Although it is inevitable that variability among
infections, tissue site, and cell type will influence which specific markers are associated
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with TRM cells, as we continue to gain more insight into TRM cell phenotypes it is possible
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Figure 2. Hobit and Blimp-1 are transcription factors associated with
CD69+ CD4+ T cells in the skin. CD4+ T cells from the draining lymph node
or primary ear of 7 week infected mice were further sorted by activation status
using CD44 in the DLN or CD69 in the skin. Hobit and Blimp-1 expression
levels were examined by qPCR.

5.4 TRM cells in disease
TRM cells have proven to be critical mediators of protection in a number of different
contexts. However, as mediators of tissue inflammation, they also have the potential to
drive pathologic effects. For example, in cutaneous T cell lymphoma, resistance against
treatment with the T cell depleting antibody Alemtuzumab (αCD52) correlates with the
persistence of a population of TRM cells that can reactivate disease once treatment is
stopped (Clark et al., 2012; Watanabe et al., 2014). Similarly, human psoriatic lesions
often recur in the same places even after treatment, and areas of recurrent disease are
also associated with a population of highly activated, TRM phenotype cells that rapidly
produce IL-17A and IL-22 in response to ex vivo restimulation (Cheuk et al., 2014).
Finally, it has recently been identified that a population of allergen-specific, lung-resident
CD4+ T cells is sufficient to drive asthmatic disease in response to antigen re-exposure
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(Hondowicz et al., 2015). Together, these data indicate that while TRM cells can provide
rapid and robust protection in the right contexts, in situations of aberrant or exacerbated
inflammation they also have the potential to directly mediate pathology.

The pathologic potential of TRM cells has important implications for leishmaniasis, a
complex and spectral disease in which immunopathology is often an issue. Our lab
alone has identified multiple contexts in which CD8+ T cells can be pathologic: 1) In
driving metastatic disease and pathology after L. braziliensis infection (Novais et al.,
2013) and, 2) As activated bystander cells that contribute to exacerbated inflammation in
an NKG2D-dependent manner (Crosby et al., 2014, 2015). If either of these CD8+ T cell
subsets were to form a tissue resident population, they would be poised to contribute to
secondary disease. With such a diverse array of clinical responses to infection, it is very
possible that leishmania-specific or bystander TRM cells could be contributing to at least
a subset of these adverse inflammatory outcomes, though the contributions of T RM cells
to human leishmaniasis have not been studied. Nonetheless, CD8+ T cell-mediated
inflammatory processes are highly upregulated in leishmania lesions (Novais et al.,
2013). We have not identified any IFNγ-producing CD8+ TRM cells in the mouse model
(data not shown), but whether or not a population of CD8+ TRM cells exists that may
perform another protective effector function remains to be determined. CD8+ T cells
have also previously been shown to be important for secondary protection in several
contexts (Belkaid et al., 2002b; Müller et al., 1994), and thus whether or not leishmaniaspecific CD8+ T cells form TRM cell populations, and the role they might play during
secondary infection, should be further studied.
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5.5 Unresolved questions about TRM cells
It is now clear that T lymphocytes in non-lymphoid tissue have an important role to play
in infection induced immunity, autoimmunity, and potentially vaccination. However, there
are still a number of unresolved questions surrounding these cells, suggesting that the
way we think about them may change significantly as we continue to gain insight into
mechanisms of their development, maintenance, and method of action. Issues
surrounding the development of TRM cells including the role of antigen, T cell intrinsic
qualities, TRM cell functions, and tissue-specific signaling have been previously
discussed in this text (Section 5.2). Similarly, a number of questions remain poorly
addressed regarding the long-term maintenance of TRM cells in tissue.

Few studies have rigorously addressed the question of how long TRM cells are
maintained in tissue after infection. At a population level, TRM cell populations appear to
be maintained at relatively stable frequencies throughout the life of a mouse (Masopust
et al., 2001; Jiang et al., 2012). Similarly in our studies, we see leishmania-specific TRM
cells maintained for roughly a year after the resolution of disease (Glennie et al., 2015),
but whether or not these cells are being reseeded from circulation remains to be
determined by long term skin graft or parabiosis studies. In parabiosis studies that have
long-term (24 weeks) post-operative follow-up, TRM cells have appeared to remain
relatively stable and not repopulate the naïve parabiont at any appreciable frequency
(Jiang et al., 2012). However, more studies of this nature will need to confirm these
findings, as there are likely tissue and infection specific differences.

If TRM cells are not being reseeded from circulation, then they are either extremely longlived and/or undergoing homeostatic turnover. Several T cell survival factors such as IL94

7, IL-15, the aryl hydrocarbon receptor, and BCL-2 have been associated with TRM cells
(Adachi et al., 2015; Schenkel et al., 2014b; Mackay et al., 2013; Zaid et al., 2014),
suggesting that they may indeed be able to survive for long periods in the tissue.
However, there appear to be tissue specific differences as CD8+ TRM cells in the female
reproductive tract could be retained independently of IL-15, while cells in the skin could
not (Schenkel et al., 2016; Adachi et al., 2015). One study has demonstrated that TRM
cells in the brain undergo homeostatic proliferation, as indicated by Ki-67 staining and
STAT5 phosphorylation. Further study will be required to determine if this is a consistent
feature of TRM cells.

Another understudied area is the impact of the microbiome on TRM cell populations. It is
clear in the gut of both mice and humans that the composition of the microbiome effects
mucosal and systemic immune responses (Smolinska et al., 2017; Schirmer et al.,
2016). It seems likely that the microbiome will potentially play a role in the
establishment, maintenance, or activation of TRM cells, but little work has yet been done
in these areas. A series of studies in the gut links the generation of different TRM cell
populations to different gut microenvironments, suggesting that the microbiome may play
a role (Bergsbaken and Bevan, 2015; Bergsbaken et al., 2017). Studies from our lab
and others have identified that changes in the microbiome can influence the course of
leishmania infection (Naik et al., 2015, 2012; Gimblet et al., 2017), and further identified
that skin inflammation can tune commensal specific resident T cell responses (Naik et
al., 2012). Whether or not the skin microbiota influences leishmania-specific TRM cell
responses remains to be defined, though preliminary data from our lab indicate that
germ-free mice have similar frequencies of TRM cells in the skin at the peak of infection
(data not shown).
95

Finally, the distribution, composition, and size of TRM cell niches in each tissue remain to
be understood. The studies that have been done suggest a high degree of variability
based on infection, tissue, and cell type. Studies in the skin initially suggested that
CD8+ cells are much more likely to be confined to epidermal niches, while CD4+ cells
are distributed within the dermis (Gebhardt et al., 2011). Follow up studies have
identified a significant role for hair follicles and hair follicle-derived signals (Adachi et al.,
2015; Collins et al., 2016), though these data remain to be confirmed in humans.
Further, there appear to be differential signals required for the retention of TRM cells in
skin and the FRT (Schenkel et al., 2016). HSV infection in the female reproductive tract
appears to generate memory lymphocyte clusters, in which myeloid cells and TRM cells
cohabitate and interact to sustain one another (Iijima and Iwasaki, 2014). TRM cells in
the skin similarly demonstrate clustering behavior in which CD4+, CD8+, and CD11c+
cells cluster together, and surprisingly CCL5+ from CD8+ cells is required for CD4+ TRM
cell retention (Collins et al., 2016). One of the least studied aspects of TRM cells is the
potential size of the TRM niche. One study in the skin suggested that CD8+ TRM cells
compete with epidermal DETC cells for niche space (Zaid et al., 2014). Our data from
figure 4.3 and data from the female reproductive tract and salivary glands (Schenkel et
al., 2016) suggest that tissue resident immune responses can be boosted by repeated
antigen exposure, suggesting that the niche can be expanded, though the upper limit
remains to be defined.

5.6 Difficulties associated with studying TRM cells
As the field of TRM cells continues to move forward, it will be important to overcome a
number of difficulties associated with studying TRM cells. While multi-parametric flow
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cytometry is a very useful technique for studying specific subsets of cells, the required
digestion of tissue involved with sample preparation can result in a massive loss of cell
number (Steinert et al., 2015), as well as a requisite loss of information regarding the
position of cells within tissue. Increasingly, fluorescent imaging is being used to combat
these issues, although there are technical difficulties associated with this technique as
well, as it is often more difficult to stain for a large number of markers and to determine
co-expression patterns. The continued development of cell-extraction and imaging
techniques could greatly enhance the capacity to study TRM cells.

The lack of a definitive signature for TRM cells also makes it difficult to study these rare
populations. Studies are often done by transferring transgenic T cells specific for one
epitope of a pathogen, challenging, and analyzing those transferred cells remaining in
the tissue after a period of time. This approach has the caveat that the response is
monoclonal, and may not be representative of what is happening during natural
infection. We were able to examine polyclonal responses in our studies, but this
required the ex vivo restimulation of cells, which has the potential to skew any
phenotypic markers. A more definitive signature for TRM cells would help combat this
issue, as it would allow TRM cells to be identified by markers alone and not require
additional manipulation.

A related issue critical for the study of TRM cells is differentiating them from their
circulating counterparts. Our group and others have taken great experimental lengths to
distinguish these populations, which often requires techniques such as transplantation of
tissue or parabiotic surgery. Again, further delineation of what defines a T RM cell may
help alleviate some of these issues. Intravascular labeling of cells in direct blood contact
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(Anderson et al., 2014) has also proven a useful resource for distinguishing blood and
tissue associated cells, though it may not be as effective for highly vascularized tissues,
and cannot distinguish true TRM cells from cells that are temporarily in tissue. In vivo
imaging with 2-photon microscopy may also allow for nonbiased analysis of migratory
and non-migratory T cell populations, though the length of time for which one can run
these analyses is limited. Fortunately, for some questions it is probably not critical to
distinguish whether a population of T cells in tissue is truly resident, but rather whether
or not they contribute to the resolution or pathogenesis of disease.

To that end, the data presented here identify skin-resident CD4+ T cells as critical
mediators of protection against cutaneous leishmaniasis. In addition to clarifying
multiple mechanisms by which these cells protect, we have identified factors associated
with the formation of this population, and even demonstrated at least one way in which
they might be generated in a vaccine. Despite the many difficulties associated with
studying tissue-resident populations, it will be important to continue to study these cells
not only as a means of understanding protection against leishmaniasis, but also as a
general tool for understanding how CD4+ T cell responses are formed and maintained in
tissue, and the role that these cells play in establishing protective immunity.

5.7 Materials and Methods

DNA Electroporation
25 µg of DNA plasmid encoding HIV-env was injected intramuscularly into the tibialis
anterior or intradermally into the side skin of C57BL/6 mice. 14 days later, the
vaccination was repeated. 10 days after the second vaccination, mice were sacrificed
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and spleen, skin from the vaccination site, and skin from the opposite side were
harvested. Spleen and skin were restimulated with overlapping 11mer peptide pools,
and IFNγ producing cells were measured by Elispot or flow cytometry.

Cell Sort and qPCR
CD4+ cells from the DLN or primary ear of C57BL/6 mice 7 weeks post L. major infection
were sorted based on CD44 expression (DLN) or CD69 expression (Ear) by FACS Aria
into RLT buffer (Qiagen). RNA was isolated using RNeasy plus pico kit (Qiagen), and
qPCR was performed for Hobit and Blimp-1 using primers (F: 5’CTCAGCCACTTGCAGACTCA-3’, R: 5’-CTGTCGGTGGAGGCTTTGTA-3’), and (F: 5’TTCTCTTGGAAAAACGTGTGGG-3’, R: 5’-GGAGCCGGAGCTAGACTTG-3’)
respectively.
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